{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:05:06Z","timestamp":1791356706712,"version":"4.3.1"},"reference-count":270,"publisher":"Bentham Science Publishers Ltd.","issue":"15","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>:<\/jats:title>\n                    <jats:p>Parkinson's disease (PD) is a neurodegenerative disease (ND) that affects many people.\nHowever, there remains no cure for PD and difficulties exist with conventional medicines. There\nhas been a lot of discussion about using nanotechnology to increase the bioavailability of smallmolecule\ndrugs to target cells in recent years. It is possible that PD treatment might become far\nmore effective and have fewer side effects if medication delivery mechanisms were to be improved.\nPotential alternatives to pharmacological therapy for molecular imaging and treatment of\nPD may lie in abnormal proteins such as parkin, \u03b1-synuclein, leucine-rich repeat serine and threonine\nprotein kinase 2. Published research has demonstrated encouraging outcomes when\nnanomedicine-based approaches are used to address the challenges of PD therapy. So, to address\nthe present difficulties of antiparkinsonian treatment, this review outlines the key issues and limitations\nof antiparkinsonian medications, new therapeutic strategies, and the breadth of delivery\nbased on nanomedicine. This review covers a wide range of subjects, including drug distribution\nin the brain, the efficacy of drug-loaded nano-carriers in crossing the blood-brain barrier, and their\nrelease profiles. In PD, the nano-carriers are also used. Novel techniques of pharmaceutical delivery\nare currently made possible by vesicular carriers, which eliminate the requirement to cross the\nblood-brain barrier (BBB).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113894501312703240826070530","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:33:20Z","timestamp":1727138000000},"page":"987-1011","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development"],"prefix":"10.2174","volume":"25","author":[{"given":"Manisha","family":"Majumdar","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Badwaik","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12889-023-15018-x","volume":"23","author":"Safiri S.","year":"2023","unstructured":"Safiri S.; Noori M.; Nejadghaderi S.A.; Mousavi S.E.; Sullman M.J.M.; Araj-Khodaei M.; Singh K.; Kolahi A.A.; Gharagozli K.; The burden of Parkinson\u2019s disease in the Middle East and North Africa region, 1990\u20132019: results from the global burden of disease study 2019. BMC Public Health  2023,23(1),107","journal-title":"BMC Public Health"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"Aarsland D.","year":"2021","unstructured":"Aarsland D.; Batzu L.; Halliday G.M.; Geurtsen G.J.; Ballard C.; Ray Chaudhuri K.; Weintraub D.; Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers  2021,7(1),47","journal-title":"Nat Rev Dis Primers"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1002\/ctd2.150","volume":"3","author":"Yang J.","year":"2023","unstructured":"Yang J.; Idowu A.; Rosenthal L.; Mao X.; Parkinson\u2019s disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes. Clin Transl Discov  2023,3(1),e150","journal-title":"Clin Transl Discov"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","volume":"10","author":"Ramesh S.","year":"2023","unstructured":"Ramesh S.; Arachchige A.S.P.M.; Depletion of dopamine in Parkinson\u2019s disease and relevant therapeutic options: A review of the literature. AIMS Neurosci  2023,10(3),200-231","journal-title":"AIMS Neurosci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"Dauer W.","year":"2003","unstructured":"Dauer W.; Przedborski S.; Parkinson\u2019s Disease. Neuron  2003,39(6),889-909","journal-title":"Neuron"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/ijerph19010364","volume":"19","author":"Sivanandy P.","year":"2021","unstructured":"Sivanandy P.; Leey T.C.; Xiang T.C.; Ling T.C.; Wey Han S.A.; Semilan S.L.A.; Hong P.K.; Systematic Review on Parkinson\u2019s Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson\u2019s Symptoms. Int J Environ Res Public Health  2021,19(1),364","journal-title":"Int J Environ Res Public Health"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"114849","DOI":"10.1016\/j.bcp.2021.114849","volume":"195","author":"Ahmad J.","year":"2022","unstructured":"Ahmad J.; Haider N.; Khan M.A.; Md S.; Alhakamy N.A.; Ghoneim M.M.; Alshehri S.; Sarim Imam S.; Ahmad M.Z.; Mishra A.; Novel therapeutic interventions for combating Parkinson\u2019s disease and prospects of Nose-to-Brain drug delivery. Biochem Pharmacol  2022,195,114849","journal-title":"Biochem Pharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2174\/1570159X18666200807143526","volume":"19","author":"Patel V.","year":"2021","unstructured":"Patel V.; Chavda V.; Shah J.; Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems. Curr Neuropharmacol  2021,19(5),693-710","journal-title":"Curr Neuropharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.3390\/pharmaceutics15112599","volume":"15","author":"Niazi S.K.","year":"2023","unstructured":"Niazi S.K.; Non-Invasive Drug Delivery across the Blood\u2013Brain Barrier: A Prospective Analysis. Pharmaceutics  2023,15(11),2599","journal-title":"Pharmaceutics"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"Wu D.","year":"2023","unstructured":"Wu D.; Chen Q.; Chen X.; Han F.; Chen Z.; Wang Y.; The blood\u2013brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther  2023,8(1),217","journal-title":"Signal Transduct Target Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.brainresbull.2022.09.017","volume":"190","author":"Zhang S.","year":"2022","unstructured":"Zhang S.; Gan L.; Cao F.; Wang H.; Gong P.; Ma C.; Ren L.; Lin Y.; Lin X.; The barrier and interface mechanisms of the brain barrier, and brain drug delivery. Brain Res Bull  2022,190,69-83","journal-title":"Brain Res Bull"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"116113","DOI":"10.1016\/j.biopha.2023.116113","volume":"171","author":"Zhao C.","year":"2024","unstructured":"Zhao C.; Zhu X.; Tan J.; Mei C.; Cai X.; Kong F.; Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment. Biomed Pharmacother  2024,171,116113","journal-title":"Biomed Pharmacother"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13205-023-03553-8","volume":"13","author":"Adam H.","year":"2023","unstructured":"Adam H.; Gopinath SCB.; Arshad MK.; Adam T.; Parmin NA.; Husein I; An update on pathogenesis and clinical scenario for Parkinson \u2019 s disease : diagnosis and treatment. 3 Biotech  2023,13(5),1-18","journal-title":"3 Biotech"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3390\/cells12121643","volume":"12","author":"De Martini L.B.","year":"2023","unstructured":"De Martini L.B.; Sulmona C.; Brambilla L.; Rossi D.; Cell-penetrating peptides as valuable tools for nose-to-brain delivery of biological drugs. Cells  2023,12(12),1643","journal-title":"Cells"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/pharmaceutics14020224","volume":"14","author":"Ayub A.","year":"2022","unstructured":"Ayub A.; Wettig S.; An overview of nanotechnologies for drug delivery to the brain. Pharmaceutics  2022,14(2),224","journal-title":"Pharmaceutics"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"107321","DOI":"10.1016\/j.isci.2023.107321","volume":"26","author":"Wu D.D.","year":"2023","unstructured":"Wu D.D.; Salah Y.A.; Ngowi E.E.; Zhang Y.X.; Khattak S.; Khan N.H.; Wang Y.; Li T.; Guo Z.H.; Wang Y.M.; Ji X.Y.; Nanotechnology prospects in brain therapeutics concerning gene-targeting and nose-to-brain administration. iScience  2023,26(8),107321","journal-title":"iScience"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12938-022-01062-y","volume":"22","author":"Shabani L.","year":"2023","unstructured":"Shabani L.; Abbasi M.; Azarnew Z.; Amani A.M.; Vaez A.; Neuro-nanotechnology: diagnostic and therapeutic nano-based strategies in applied neuroscience. Biomed Eng Online  2023,22(1),1","journal-title":"Biomed Eng Online"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"104774","DOI":"10.1016\/j.jddst.2023.104774","volume":"87","author":"Mustafa G.","year":"2023","unstructured":"Mustafa G.; Hassan D.; Zeeshan M.; Ruiz-Pulido G.; Ebrahimi N.; Mobashar A.; Pourmadadi M.; Rahdar A.; Sargazi S.; Fathi-karkan S.; Medina D.I.; D\u00edez-Pascual A.M.; Advances in nanotechnology versus stem cell therapy for the theranostics of Huntington\u2019s disease. J Drug Deliv Sci Technol  [Internet].2023,87,104774","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3390\/polym15071596","volume":"15","author":"Yusuf A.","year":"2023","unstructured":"Yusuf A.; Almotairy A.R.Z.; Henidi H.; Alshehri O.Y.; Aldughaim M.S.; Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles\u2019 Physicochemical Properties on Responses in Biological Systems. Polymers (Basel)  2023,15(7),1596","journal-title":"Polymers (Basel)"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","volume":"22","author":"Chehelgerdi M.","year":"2023","unstructured":"Chehelgerdi M.; Chehelgerdi M.; Allela O.Q.B.; Pecho R.D.C.; Jayasankar N.; Rao D.P.; Thamaraikani T.; Vasanthan M.; Viktor P.; Lakshmaiya N.; Saadh M.J.; Amajd A.; Abo-Zaid M.A.; Castillo-Acobo R.Y.; Ismail A.H.; Amin A.H.; Akhavan-Sigari R.; Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer  2023,22(1),169","journal-title":"Mol Cancer"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00228-020-03081-x","volume":"77","author":"Artusi C.A.","year":"2021","unstructured":"Artusi C.A.; Sarro L.; Imbalzano G.; Fabbri M.; Lopiano L.; Safety and efficacy of tolcapone in Parkinson\u2019s disease: systematic review. Eur J Clin Pharmacol  2021,77(6),817-829","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/17460441.2020.1767580","volume":"15","author":"Ettcheto M.","year":"2020","unstructured":"Ettcheto M.; Busquets O.; S\u00e1nchez-Lopez E.; Cano A.; Manzine P.R.; Verdaguer E.; Olloquequi J.; Auladell C.; Folch J.; Camins A.; The preclinical discovery and development of opicapone for the treatment of Parkinson\u2019s disease. Expert Opin Drug Discov  2020,15(9),993-1003","journal-title":"Expert Opin Drug Discov"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s12640-016-9663-z","volume":"30","author":"Hawthorne G.H.","year":"2016","unstructured":"Hawthorne G.H.; Bernuci M.P.; Bortolanza M.; Tumas V.; Issy A.C.; Del-Bel E.; Nanomedicine to overcome current Parkinson\u2019s treatment liabilities: A systematic review. Neurotox Res  2016,30(4),715-729","journal-title":"Neurotox Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.xphs.2020.12.010","volume":"110","author":"Itin C.","year":"2021","unstructured":"Itin C.; Komargodski R.; Barasch D.; Domb A.J.; Hoffman A.; prolonged delivery of apomorphine through the buccal mucosa, towards a noninvasive sustained administration method in Parkinson\u2019s disease: in vivo investigations in pigs. J Pharm Sci  2021,110(4),1824-1833","journal-title":"J Pharm Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3109\/1061186X.2015.1020809","volume":"23","author":"Kulkarni A.D.","year":"2015","unstructured":"Kulkarni A.D.; Vanjari Y.H.; Sancheti K.H.; Belgamwar V.S.; Surana S.J.; Pardeshi C.V.; Nanotechnology-mediated nose to brain drug delivery for Parkinson\u2019s disease: a mini review. J Drug Target  2015,23(9),775-788","journal-title":"J Drug Target"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2174\/1570159X20666220507022701","volume":"21","author":"Khatri D.K.","year":"2023","unstructured":"Khatri D.K.; Preeti K.; Tonape S.; Bhattacharjee S.; Patel M.; Shah S.; Singh P.K.; Srivastava S.; Gugulothu D.; Vora L.; Singh S.B.; Nanotechnological advances for nose to brain delivery of therapeutics to improve the Parkinson therapy. Curr Neuropharmacol  2023,21(3),493-516","journal-title":"Curr Neuropharmacol"},{"key":"ref=27","first-page":"23","author":"Gursoy A.","year":"2014","unstructured":"Gursoy A.;  Nanofarmas\u00f6tikler ve Uygulamalar\u0131  2014,23-40","journal-title":"Nanofarmas\u00f6tikler ve Uygulamalar\u0131"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1749-6632.2009.05108.x","volume":"1184","author":"Modi G.","year":"2010","unstructured":"Modi G.; Pillay V.; Choonara Y.E.; Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann N Y Acad Sci  2010,1184(1),154-172","journal-title":"Ann N Y Acad Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1039\/b307062j","volume":"34","author":"Kostarelos K.","year":"2005","unstructured":"Kostarelos K.; Miller A.D.; Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors. Chem Soc Rev  2005,34(11),970-994","journal-title":"Chem Soc Rev"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1517\/17425247.5.1.105","volume":"5","author":"Foged C.","year":"2008","unstructured":"Foged C.; Nielsen H.M.; Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv  2008,5(1),105-117","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1002\/0470864052","author":"Gielen M.E.R.","year":"2005","unstructured":"Gielen M.E.R.;  Metallotherapeutic drugs and metal-based diagnostic agents: The use of metals in medicine  2005","journal-title":"Metallotherapeutic drugs and metal-based diagnostic agents: The use of metals in medicine"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1080\/10590501.2013.829706","volume":"31","author":"Iqbal A.","year":"2013","unstructured":"Iqbal A.; Ahmad I.; Khalid M.H.; Nawaz M.S.; Gan S.H.; Kamal M.A.; Nanoneurotoxicity to nanoneuroprotection using biological and computational approaches. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev  2013,31(3),256-284","journal-title":"J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1126\/science.1095833","volume":"303","author":"Allen T.M.","year":"2004","unstructured":"Allen T.M.; Cullis P.R.; Drug delivery systems: entering the mainstream. Science  2004,303(5665),1818-1822","journal-title":"Science"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1021\/nn900002m","volume":"3","author":"Farokhzad O.C.","year":"2009","unstructured":"Farokhzad O.C.; Langer R.; Impact of nanotechnology on drug delivery. ACS Nano  2009,3(1),16-20","journal-title":"ACS Nano"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jconrel.2011.08.017","volume":"161","author":"Wohlfart S.","year":"2012","unstructured":"Wohlfart S.; Gelperina S.; Kreuter J.; Transport of drugs across the blood\u2013brain barrier by nanoparticles. J Control Release  2012,161(2),264-273","journal-title":"J Control Release"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/molecules23010040","volume":"23","author":"Haddad F.","year":"2017","unstructured":"Haddad F.; Sawalha M.; Khawaja Y.; Najjar A.; Karaman R.; Dopamine and levodopa prodrugs for the treatment of Parkinson\u2019sdisease. Molecules  2017,23(1),40","journal-title":"Molecules"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/btpr.1835","volume":"30","author":"Shin M.","year":"2014","unstructured":"Shin M.; Kim H.K.; Lee H.; Dopamine-loaded poly(,-lactic-co-glycolic acid) microspheres: New strategy for encapsulating small hydrophilic drugs with high efficiency. Biotechnol Prog  2014,30(1),215-223","journal-title":"Biotechnol Prog"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1021\/nn506408v","volume":"9","author":"Pahuja R.","year":"2015","unstructured":"Pahuja R.; Seth K.; Shukla A.; Shukla R.K.; Bhatnagar P.; Chauhan L.K.S.; Saxena P.N.; Arun J.; Chaudhari B.P.; Patel D.K.; Singh S.P.; Shukla R.; Khanna V.K.; Kumar P.; Chaturvedi R.K.; Gupta K.C.; Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats. ACS Nano  2015,9(5),4850-4871","journal-title":"ACS Nano"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"15185","DOI":"10.1038\/s41598-021-94175-8","volume":"11","author":"Monge-Fuentes V.","year":"2021","unstructured":"Monge-Fuentes V.; Biolchi Mayer A.; Lima M.R.; Geraldes L.R.; Zanotto L.N.; Moreira K.G.; Martins O.P.; Piva H.L.; Felipe M.S.S.; Amaral A.C.; Bocca A.L.; Tedesco A.C.; Mortari M.R.; Dopamine-loaded nanoparticle systems circumvent the blood\u2013brain barrier restoring motor function in mouse model for Parkinson\u2019s Disease. Sci Rep  2021,11(1),15185","journal-title":"Sci Rep"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.2147\/IJN.S120939","volume":"11","author":"Bi C.","year":"2016","unstructured":"Bi C.; Wang A.; Chu Y.; Liu S.; Mu H.; Liu W.; Wu Z.; Sun K.; Li Y.; Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson\u2019s disease treatment. Int J Nanomedicine  2016,11,6547-6559","journal-title":"Int J Nanomedicine"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1016\/j.nano.2018.08.004","volume":"14","author":"Sridhar V.","year":"2018","unstructured":"Sridhar V.; Gaud R.; Bajaj A.; Wairkar S.; Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson\u2019s disease. Nanomedicine  2018,14(8),2609-2618","journal-title":"Nanomedicine"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3109\/03639045.2013.789051","volume":"40","author":"Sharma S.","year":"2014","unstructured":"Sharma S.; Lohan S.; Murthy R.S.R.; Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm  2014,40(7),869-878","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.ijbiomac.2020.06.261","volume":"164","author":"Bali N.R.","year":"2020","unstructured":"Bali N.R.; Salve P.S.; Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: A nanotheranostic perspective for Parkinsonism. Int J Biol Macromol  2020,164,1006-1024","journal-title":"Int J Biol Macromol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"101299","DOI":"10.1016\/j.jddst.2019.101299","volume":"54","author":"Bali N.R.","year":"2019","unstructured":"Bali N.R.; Salve P.S.; Selegiline nanoparticle embedded transdermal film: An alternative approach for brain targeting in Parkinson\u2019s disease. J Drug Deliv Sci Technol  [CrossRef].2019,54,101299","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=45","first-page":"2077","volume":"7","author":"Yang X.","year":"2012","unstructured":"Yang X.; Zheng R.; Cai Y.; Liao M.; Yuan W.; Liu Z.; Controlled-release levodopa methyl ester\/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. Int J Nanomedicine  [CrossRef].2012,7,2077-2086","journal-title":"Int J Nanomedicine"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijbiomac.2017.12.056","volume":"109","author":"Raj R.","year":"2018","unstructured":"Raj R.; Wairkar S.; Sridhar V.; Gaud R.; Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol  2018,109,27-35","journal-title":"Int J Biol Macromol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/cbdd.13681","volume":"95","author":"Meng X.Y.","year":"2020","unstructured":"Meng X.Y.; Huang A.Q.; Khan A.; Zhang L.; Sun X.Q.; Song H.; Han J.; Sun Q.R.; Wang Y.D.; Li X.L.; Vascular endothelial growth factor-loaded poly-lactic-co-glycolic acid nanoparticles with controlled release protect the dopaminergic neurons in Parkinson\u2019s rats. Chem Biol Drug Des  2020,95(6),631-639","journal-title":"Chem Biol Drug Des"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ijpharm.2009.08.021","volume":"382","author":"Pillay S.","year":"2009","unstructured":"Pillay S.; Pillay V.; Choonara Y.E.; Naidoo D.; Khan R.A.; du Toit L.C.; Ndesendo V.M.K.; Modi G.; Danckwerts M.P.; Iyuke S.E.; Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. Int J Pharm  2009,382(1-2),277-290","journal-title":"Int J Pharm"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jddst.2018.08.016","volume":"48","author":"Ray S.","year":"2018","unstructured":"Ray S.; Sinha P.; Laha B.; Maiti S.; Bhattacharyya U.K.; Nayak A.K.; Polysorbate 80 coated crosslinked chitosan nanoparticles of ropinirole hydrochloride for brain targeting. J Drug Deliv Sci Technol  [CrossRef].2018,48,21-29","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=50","first-page":"1","author":"Sudhir Dhote N.","year":"2024","unstructured":"Sudhir Dhote N.; Dineshbhai Patel R.; Kuwar U.; Agrawal M.; Alexander A.; Jain P.; Application of Thermoresponsive Smart Polymers based in situ Gel as a Novel Carrier for Tumor Targeting [Internet]. Vol. 24. Curr Cancer Drug Targets  2024,1-22","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.matpr.2023.01.147","volume":"83","author":"Bhairam M.","year":"2023","unstructured":"Bhairam M.; Prasad J.; Verma K.; Jain P.; Gidwani B.; Formulation of transdermal patch of Losartan Potassium and Glipizide for the treatment of hypertension and diabetes. Mater Today Proc  [Internet].2023,83,59-68","journal-title":"Mater Today Proc"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2174\/1567201820666230112170035","volume":"21","author":"Patel R.","year":"2024","unstructured":"Patel R.; Kuwar U.; Dhote N.; Alexander A.; Nakhate K.; Jain P.; Ajazuddin ; Natural Polymers as a Carrier for the Effective Delivery of Antineoplastic Drugs. Curr Drug Deliv  2024,21(2),193-210","journal-title":"Curr Drug Deliv"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12029-021-00788-7","volume":"54","author":"Jain A.","year":"2023","unstructured":"Jain A.; Jain P.; Soni P.; Tiwari A.; Tiwari S.P.; Design and Characterization of Silver Nanoparticles of Different Species of Curcuma in the Treatment of Cancer Using Human Colon Cancer Cell Line (HT-29). J Gastrointest Cancer  2023,54(1),90-95","journal-title":"J Gastrointest Cancer"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"102700","DOI":"10.1016\/j.bcab.2023.102700","volume":"50","author":"Islam M.","year":"2023","unstructured":"Islam M.; Huang Y.; Jain P.; Fan B.; Tong L.; Wang F.; Enzymatic hydrolysis of soy protein to high moisture textured meat analogue with emphasis on antioxidant effects: As a tool to improve techno-functional property. Biocatal Agric Biotechnol  [Internet].2023,50,102700","journal-title":"Biocatal Agric Biotechnol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"14439","DOI":"10.1002\/chem.201001654","volume":"16","author":"An Y.","year":"2010","unstructured":"An Y.; Tang L.; Jiang X.; Chen H.; Yang M.; Jin L.; Zhang S.; Wang C.; Zhang W.; A photoelectrochemical immunosensor based on Au-doped TiO2 nanotube arrays for the detection of \u03b1-synuclein. Chemistry  2010,16(48),14439-14446","journal-title":"Chemistry"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"26777","DOI":"10.1039\/D0RA03491F","volume":"10","author":"Duan Y.","year":"2020","unstructured":"Duan Y.; Dhar A.; Patel C.; Khimani M.; Neogi S.; Sharma P.; Siva Kumar N.; Vekariya R.L.; A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Advances  2020,10(45),26777-26791","journal-title":"RSC Advances"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"114485","DOI":"10.1016\/j.addr.2022.114485","volume":"189","author":"Correia A.C.","year":"2022","unstructured":"Correia A.C.; Monteiro A.R.; Silva R.; Moreira J.N.; Sousa Lobo J.M.; Silva A.C.; Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood\u2013brain barrier (BBB) to manage neurological disorders. Adv Drug Deliv Rev  2022,189,114485","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"111073","DOI":"10.1016\/j.colsurfb.2020.111073","volume":"193","author":"Diwan R.","year":"2020","unstructured":"Diwan R.; Ravi P.R.; Pathare N.S.; Aggarwal V.; Pharmacodynamic, pharmacokinetic and physical characterization of cilnidipine loaded solid lipid nanoparticles for oral delivery optimized using the principles of design of experiments. Colloids Surf B Biointerfaces  2020,193,111073","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/pharmaceutics13122049","volume":"13","author":"Lee D.","year":"2021","unstructured":"Lee D.; Minko T.; Nanotherapeutics for nose-to-brain drug delivery: An approach to bypass the blood brain barrier. Pharmaceutics  2021,13(12),2049","journal-title":"Pharmaceutics"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/jps.22285","volume":"100","author":"Tsai M.J.","year":"2011","unstructured":"Tsai M.J.; Huang Y.B.; Wu P.C.; Fu Y.S.; Kao Y.R.; Fang J.Y.; Tsai Y.H.; Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci  2011,100(2),547-557","journal-title":"J Pharm Sci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"120881","DOI":"10.1016\/j.ijpharm.2021.120881","volume":"606","author":"Uppuluri C.T.","year":"2021","unstructured":"Uppuluri C.T.; Ravi P.R.; Dalvi A.V.; Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson\u2019s disease. Int J Pharm  2021,606,120881","journal-title":"Int J Pharm"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3390\/pharmaceutics12050448.","volume":"12","author":"Dudhipala N.","year":"2020","unstructured":"Dudhipala N.; Gorre T.; Neuroprotective effect of ropinirole lipid nanoparticles enriched hydrogel for parkinson's disease: in vitro, ex-vivo, pharmacokinetic and pharmacodynamic evaluation. Pharmaceutics  2020,12(5),448","journal-title":"Pharmaceutics"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/10667857.2019.1674522","volume":"35","author":"Pardeshi C.V.","year":"2020","unstructured":"Pardeshi C.V.; Belgamwar V.S.; Improved brain pharmacokinetics following intranasal administration of N,N,N -trimethyl chitosan tailored mucoadhesive NLCs. Mater Technol  [CrossRef].2020,35(5),249-266","journal-title":"Mater Technol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1023\/A:1010931127745","volume":"18","author":"Calvo P.","year":"2001","unstructured":"Calvo P.; Gouritin B.; Chacun H.; Desma\u00eble D.; D\u2019Angelo J.; Noel J.P.; Georgin D.; Fattal E.; Andreux J.P.; Couvreur P.; Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res  2001,18(8),1157-1166","journal-title":"Pharm Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"618411","DOI":"10.3389\/fphar.2021.618411","volume":"12","author":"Alqahtani M.S.","year":"2021","unstructured":"Alqahtani M.S.; Kazi M.; Alsenaidy M.A.; Ahmad M.Z.; Advances in oral drug delivery. Front Pharmacol  2021,12,618411","journal-title":"Front Pharmacol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3390\/ph15080975","volume":"15","author":"Azman M.","year":"2022","unstructured":"Azman M.; Sabri A.H.; Anjani Q.K.; Mustaffa M.F.; Hamid K.A.; Intestinal absorption study: Challenges and absorption enhancement strategies in improving oral drug delivery. Pharmaceuticals (Basel)  2022,15(8),975","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/978-1-4614-0554-2_10","author":"Wang Y.","year":"2012","unstructured":"Wang Y.; Burgess D.J.;  Long Acting Injections and Implants  2012,167-194","journal-title":"Long Acting Injections and Implants"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1021\/cr940351u","volume":"99","author":"Uhrich K.E.","year":"1999","unstructured":"Uhrich K.E.; Cannizzaro S.M.; Langer R.S.; Shakesheff K.M.; Polymeric systems for controlled drug release. Chem Rev  1999,99(11),3181-3198","journal-title":"Chem Rev"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3109\/03639049809082719","volume":"24","author":"Jain R.","year":"1998","unstructured":"Jain R.; Shah N.H.; Malick A.W.; Rhodes C.T.; Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev Ind Pharm  1998,24(8),703-727","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2016016624","volume":"33","author":"Abadi S.S.H.","year":"2016","unstructured":"Abadi S.S.H.; Moin A.; Veerabhadrappa G.H.; Fabricated microparticles: An innovative method to minimize the side effects of NSAIDs in arthritis. Crit Rev Ther Drug Carrier Syst  2016,33(5),433-488","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.01.027","volume":"407","author":"Tran V.T.","year":"2011","unstructured":"Tran V.T.; Beno\u00eet J.P.; Venier-Julienne M.C.; Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy? Int J Pharm  2011,407(1-2),1-11","journal-title":"Int J Pharm"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1080\/10717544.2022.2072413","volume":"29","author":"Su Y.","year":"2022","unstructured":"Su Y.; Liu J.; Tan S.; Liu W.; Wang R.; Chen C.; PLGA sustained-release microspheres loaded with an insoluble small-molecule drug: microfluidic-based preparation, optimization, characterization, and evaluation in vitro and in vivo. Drug Deliv  2022,29(1),1437-1446","journal-title":"Drug Deliv"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/10717544.2021.1938756","volume":"28","author":"Su Y.","year":"2021","unstructured":"Su Y.; Zhang B.; Sun R.; Liu W.; Zhu Q.; Zhang X.; Wang R.; Chen C.; PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application. Drug Deliv  2021,28(1),1397-1418","journal-title":"Drug Deliv"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jconrel.2021.06.017","volume":"336","author":"O\u2019Brien M.N.","year":"2021","unstructured":"O\u2019Brien M.N.; Jiang W.; Wang Y.; Loffredo D.M.; Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release  2021,336,144-158","journal-title":"J Control Release"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jconrel.2020.06.023","volume":"325","author":"Sharifi F.","year":"2020","unstructured":"Sharifi F.; Otte A.; Yoon G.; Park K.; Continuous in-line homogenization process for scale-up production of naltrexone-loaded PLGA microparticles. J Control Release  2020,325,347-358","journal-title":"J Control Release"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/wrr.12404","volume":"24","author":"Chereddy K.K.","year":"2016","unstructured":"Chereddy K.K.; Vandermeulen G.; Pr\u00e9at V.; PLGA based drug delivery systems: Promising carriers for wound healing activity. Wound Repair Regen  2016,24(2),223-236","journal-title":"Wound Repair Regen"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jconrel.2004.10.015","volume":"102","author":"Freitas S.","year":"2005","unstructured":"Freitas S.; Merkle H.P.; Gander B.; Microencapsulation by solvent extraction\/evaporation: reviewing the state of the art of microsphere preparation process technology. J Control Release  2005,102(2),313-332","journal-title":"J Control Release"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.msec.2015.12.004","volume":"60","author":"Lee J.","year":"2016","unstructured":"Lee J.; Kwon H.J.; Ji H.; Cho S.H.; Cho E.H.; Han H.D.; Shin B.C.; Marbofloxacin-encapsulated microparticles provide sustained drug release for treatment of veterinary diseases. Mater Sci Eng C  2016,60,511-517","journal-title":"Mater Sci Eng C"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ijpharm.2016.01.020","volume":"499","author":"Ramazani F.","year":"2016","unstructured":"Ramazani F.; Chen W.; van Nostrum C.F.; Storm G.; Kiessling F.; Lammers T.; Hennink W.E.; Kok R.J.; Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: State-of-the-art and challenges. Int J Pharm  2016,499(1-2),358-367","journal-title":"Int J Pharm"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1517\/17425247.2.6.1039","volume":"2","author":"Shi Y.","year":"2005","unstructured":"Shi Y.; Li L.; Current advances in sustained-release systems for parenteral drug delivery. Expert Opin Drug Deliv  2005,2(6),1039-1058","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1023\/A:1026498209874","volume":"17","author":"van de Weert M.","year":"2000","unstructured":"van de Weert M.; Hennink W.E.; Jiskoot W.; Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res  2000,17(10),1159-1167","journal-title":"Pharm Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fbioe.2019.00087","volume":"7","author":"Wissing T.B.","year":"2019","unstructured":"Wissing T.B.; Bonito V.; van Haaften E.E.; van Doeselaar M.; Brugmans M.M.C.P.; Janssen H.M.; Bouten C.V.C.; Smits A.I.P.M.; Macrophagedriven biomaterial degradation depends on scaffold microarchitecture. Front Bioeng Biotechnol  2019,7,87","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ijpharm.2005.03.035","volume":"298","author":"Foged C.","year":"2005","unstructured":"Foged C.; Brodin B.; Frokjaer S.; Sundblad A.; Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm  2005,298(2),315-322","journal-title":"Int J Pharm"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0168-3659(03)00194-9","volume":"90","author":"Sinha V.R.","year":"2003","unstructured":"Sinha V.R.; Trehan A.; Biodegradable microspheres for protein delivery. J Control Release  2003,90(3),261-280","journal-title":"J Control Release"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijpharm.2016.08.032","volume":"514","author":"Gasmi H.","year":"2016","unstructured":"Gasmi H.; Siepmann F.; Hamoudi M.C.; Danede F.; Verin J.; Willart J.F.; Siepmann J.; Towards a better understanding of the different release phases from PLGA microparticles: Dexamethasone-loaded systems. Int J Pharm  2016,514(1),189-199","journal-title":"Int J Pharm"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"120220","DOI":"10.1016\/j.ijpharm.2021.120220","volume":"596","author":"Tamani F.","year":"2021","unstructured":"Tamani F.; Bassand C.; Hamoudi M.C.; Siepmann F.; Siepmann J.; Mechanistic explanation of the (up to) 3 release phases of PLGA microparticles: Monolithic dispersions studied at lower temperatures. Int J Pharm  2021,596,120220","journal-title":"Int J Pharm"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13018-022-02985-x","volume":"17","author":"Shi Z.","year":"2022","unstructured":"Shi Z.; Fan Z.; Zhang H.; Li S.; Yuan H.; Tong J.; Localized delivery of brain-derived neurotrophic factor from PLGA microspheres promotes peripheral nerve regeneration in rats. J Orthop Surg Res  2022,17(1),172","journal-title":"J Orthop Surg Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.ejpb.2013.03.034","volume":"85","author":"Herr\u00e1n E.","year":"2013","unstructured":"Herr\u00e1n E.; Ruiz-Ortega J.\u00c1.; Aristieta A.; Igartua M.; Requejo C.; Lafuente J.V.; Ugedo L.; Pedraz J.L.; Hern\u00e1ndez R.M.; in vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson\u2019s disease. Eur J Pharm Biopharm  2013,85(3),1183-1190","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2019.05.013","volume":"141","author":"Li S.","year":"2019","unstructured":"Li S.; Liu J.; Li G.; Zhang X.; Xu F.; Fu Z.; Teng L.; Li Y.; Sun F.; Near-infrared light-responsive, pramipexole-loaded biodegradable PLGA microspheres for therapeutic use in Parkinson\u2019s disease. Eur J Pharm Biopharm  2019,141,1-11","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s13346-019-00625-2","volume":"9","author":"Kanwar N.","year":"2019","unstructured":"Kanwar N.; Bhandari R.; Kuhad A.; Sinha V.R.; Polycaprolactone-based neurotherapeutic delivery of rasagiline targeting behavioral and biochemical deficits in Parkinson\u2019s disease. Drug Deliv Transl Res  2019,9(5),891-905","journal-title":"Drug Deliv Transl Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s13346-013-0189-0","volume":"4","author":"Agbay A.","year":"2014","unstructured":"Agbay A.; Mohtaram N.K.; Willerth S.M.; Controlled release of glial cell line-derived neurotrophic factor from poly(\u03b5-caprolactone) microspheres. Drug Deliv Transl Res  2014,4(2),159-170","journal-title":"Drug Deliv Transl Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s10853-018-2819-x","volume":"54","author":"Parthipan A.K.","year":"2019","unstructured":"Parthipan A.K.; Gupta N.; Pandey K.; Sharma B.; Jacob J.; Saha S.; One-step fabrication of bicompartmental microparticles as a dual drug delivery system for Parkinson\u2019s disease management. J Mater Sci  2019,54(1),730-744","journal-title":"J Mater Sci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1208\/s12249-016-0653-5","volume":"18","author":"Kashif P.M.","year":"2017","unstructured":"Kashif P.M.; Madni A.; Ashfaq M.; Rehman M.; Mahmood M.A.; Khan M.I.; Tahir N.; Development of eudragit RS 100 microparticles loaded with ropinirole: Optimization and in vitro evaluation studies. AAPS PharmSciTech  2017,18(5),1810-1822","journal-title":"AAPS PharmSciTech"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.biomaterials.2016.09.015","volume":"110","author":"Garbayo E.","year":"2016","unstructured":"Garbayo E.; Ansorena E.; Lana H.; Carmona-Abellan M.M.; Marcilla I.; Lanciego J.L.; Luquin M.R.; Blanco-Prieto M.J.; Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys. Biomaterials  2016,110,11-23","journal-title":"Biomaterials"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ijpharm.2011.07.029","volume":"419","author":"Fern\u00e1ndez M.","year":"2011","unstructured":"Fern\u00e1ndez M.; Negro S.; Slowing K.; Fern\u00e1ndez-Carballido A.; Barcia E.; An effective novel delivery strategy of rasagiline for Parkinson\u2019s disease. Int J Pharm  2011,419(1-2),271-280","journal-title":"Int J Pharm"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40120-022-00435-8","volume":"12","author":"Fabbri M.","year":"2023","unstructured":"Fabbri M.; Barbosa R.; Rascol O.; Off-time treatment options for Parkinson\u2019s disease. Neurol Ther  2023,12(2),391-424","journal-title":"Neurol Ther"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ijpharm.2011.02.036","volume":"409","author":"D\u2019Aurizio E.","year":"2011","unstructured":"D\u2019Aurizio E.; van Nostrum C.F.; van Steenbergen M.J.; Sozio P.; Siepmann F.; Siepmann J.; Hennink W.E.; Di Stefano A.; Preparation and characterization of poly(lactic-co-glycolic acid) microspheres loaded with a labile antiparkinson prodrug. Int J Pharm  2011,409(1-2),289-296","journal-title":"Int J Pharm"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1021\/mp200337h","volume":"8","author":"D\u2019Aurizio E.","year":"2011","unstructured":"D\u2019Aurizio E.; Sozio P.; Cerasa L.S.; Vacca M.; Brunetti L.; Orlando G.; Chiavaroli A.; Kok R.J.; Hennink W.E.; Di Stefano A.; Biodegradable microspheres loaded with an anti-Parkinson prodrug: an in vivo pharmacokinetic study. Mol Pharm  2011,8(6),2408-2415","journal-title":"Mol Pharm"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1007\/s13197-020-04360-2","volume":"57","author":"Subramani T.","year":"2020","unstructured":"Subramani T.; Ganapathyswamy H.; An overview of liposomal nano-encapsulation techniques and its applications in food and nutraceutical. J Food Sci Technol  2020,57(10),3545-3555","journal-title":"J Food Sci Technol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.apsb.2021.05.002","volume":"11","author":"Shi Y.","year":"2021","unstructured":"Shi Y.; Lu A.; Wang X.; Belhadj Z.; Wang J.; Zhang Q.; A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives. Acta Pharm Sin B  2021,11(8),2396-2415","journal-title":"Acta Pharm Sin B"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","volume":"134","author":"Grassin-Delyle S.","year":"2012","unstructured":"Grassin-Delyle S.; Buenestado A.; Naline E.; Faisy C.; Blouquit-Laye S.; Couderc L.J.; Le Guen M.; Fischler M.; Devillier P.; Intranasal drug delivery: An efficient and non-invasive route for systemic administration. Pharmacol Ther  2012,134(3),366-379","journal-title":"Pharmacol Ther"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuroscience.2014.05.019","volume":"274","author":"Migliore M.M.","year":"2014","unstructured":"Migliore M.M.; Ortiz R.; Dye S.; Campbell R.B.; Amiji M.M.; Waszczak B.L.; Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson\u2019s disease. Neuroscience  2014,274,11-23","journal-title":"Neuroscience"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/1061186X.2011.595490","volume":"20","author":"Xiang Y.","year":"2012","unstructured":"Xiang Y.; Wu Q.; Liang L.; Wang X.; Wang J.; Zhang X.; Pu X.; Zhang Q.; Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson\u2019s disease in the MPTP-induced mice model. J Drug Target  2012,20(1),67-75","journal-title":"J Drug Target"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"102313","DOI":"10.1016\/j.jddst.2020.102313","volume":"61","author":"Trivedi R.","year":"2021","unstructured":"Trivedi R.; Umekar M.; Kotagale N.; Bonde S.; Taksande J.; Design, evaluation and in vivo pharmacokinetic study of a cationic flexible liposomes for enhanced transdermal delivery of pramipexole. J Drug Deliv Sci Technol  2021,61,102313","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.tins.2007.03.006","volume":"30","author":"Bj\u00f6rklund A.","year":"2007","unstructured":"Bj\u00f6rklund A.; Dunnett S.B.; Dopamine neuron systems in the brain: an update. Trends Neurosci  2007,30(5),194-202","journal-title":"Trends Neurosci"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1021\/acs.molpharmaceut.7b00405","volume":"14","author":"Cassano T.","year":"2017","unstructured":"Cassano T.; Lopalco A.; de Candia M.; Laquintana V.; Lopedota A.; Cutrignelli A.; Perrone M.; Iacobazzi R.M.; Bedse G.; Franco M.; Denora N.; Altomare C.D.; Oxazepam-dopamine conjugates increase dopamine delivery into striatum of intact rats. Mol Pharm  2017,14(9),3178-3187","journal-title":"Mol Pharm"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijpharm.2012.08.023","volume":"437","author":"Denora N.","year":"2012","unstructured":"Denora N.; Cassano T.; Laquintana V.; Lopalco A.; Trapani A.; Cimmino C.S.; Laconca L.; Giuffrida A.; Trapani G.; Novel codrugs with GABAergic activity for dopamine delivery in the brain. Int J Pharm  2012,437(1-2),221-231","journal-title":"Int J Pharm"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/nano8030178","volume":"8","author":"Lopalco A.","year":"2018","unstructured":"Lopalco A.; Cutrignelli A.; Denora N.; Lopedota A.; Franco M.; Laquintana V.; Transferrin functionalized liposomes loading dopamine HCl: Development and permeability studies across an in vitro model of human blood-brain barrier. Nanomaterials (Basel)  2018,8(3),178","journal-title":"Nanomaterials (Basel)"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/B978-0-12-384935-9.10008-2","author":"Rekha M.R.","year":"2011","unstructured":"Rekha M.R.; Sharma P.; Nanoparticle Mediated Oral Delivery of Peptides and Proteins: Challenges and Perspectives. Peptide and Protein Delivery  2011,165-194","journal-title":"Peptide and Protein Delivery"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9184284","volume":"2020","author":"Jin K.T.","year":"2020","unstructured":"Jin K.T.; Lu Z.B.; Chen J.Y.; Liu Y.Y.; Lan H.R.; Dong H.Y.; Yang F.; Zhao Y.Y.; Chen X.Y.; Recent Trends in Nanocarrier-Based Targeted Chemotherapy: Selective Delivery of Anticancer Drugs for Effective Lung, Colon, Cervical, and Breast Cancer Treatment. J Nanomater  [CrossRef].2020,2020,1-14","journal-title":"J Nanomater"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ijpharm.2016.10.031","volume":"515","author":"Tam V.H.","year":"2016","unstructured":"Tam V.H.; Sosa C.; Liu R.; Yao N.; Priestley R.D.; Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier. Int J Pharm  2016,515(1-2),331-342","journal-title":"Int J Pharm"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1039\/D0BM00809E","volume":"8","author":"Masoudi Asil S.","year":"2020","unstructured":"Masoudi Asil S.; Ahlawat J.; Guillama Barroso G.; Narayan M.; Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases. Biomater Sci  [CrossRef].2020,8(15),4109-4128","journal-title":"Biomater Sci"},{"key":"ref=113","first-page":"7135","volume":"2010","author":"Rahman M.M.","year":"2020","unstructured":"Rahman M.M.; Ferdous K.S.; Ahmed M.; Emerging promise of nanoparticle-based treatment for Parkinson\u2019s disease. Biointerface Res Appl Chem  2020,2010,7135-7151","journal-title":"Biointerface Res Appl Chem"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/mi13091449","volume":"13","author":"De Marco I.","year":"2022","unstructured":"De Marco I.; Supercritical Fluids and Nanoparticles in Cancer Therapy. Micromachines (Basel)  2022,13(9),1449","journal-title":"Micromachines (Basel)"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.biopha.2018.12.133","volume":"111","author":"Saeedi M.","year":"2019","unstructured":"Saeedi M.; Eslamifar M.; Khezri K.; Dizaj S.M.; Applications of nanotechnology in drug delivery to the central nervous system. Biomed Pharmacother  2019,111,666-675","journal-title":"Biomed Pharmacother"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1700897","DOI":"10.1002\/advs.201700897","volume":"5","author":"Moscariello P.","year":"2018","unstructured":"Moscariello P.; Ng D.Y.W.; Jansen M.; Weil T.; Luhmann H.J.; Hedrich J.; Brain Delivery of Multifunctional Dendrimer Protein Bioconjugates. Adv Sci (Weinh)  2018,5(5),1700897","journal-title":"Adv Sci (Weinh)"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ijantimicag.2018.12.012","volume":"53","author":"Holmes A.M.","year":"2019","unstructured":"Holmes A.M.; Heylings J.R.; Wan K.W.; Moss G.P.; Antimicrobial efficacy and mechanism of action of poly(amidoamine) (PAMAM) dendrimers against opportunistic pathogens. Int J Antimicrob Agents  2019,53(4),500-507","journal-title":"Int J Antimicrob Agents"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1021\/la036299r","volume":"20","author":"Esumi K.","year":"2004","unstructured":"Esumi K.; Houdatsu H.; Yoshimura T.; Antioxidant action by gold- PAMAM dendrimer nanocomposites. Langmuir  2004,20(7),2536-2538","journal-title":"Langmuir"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/pharmaceutics12090874","volume":"12","author":"Ortega M.A.","year":"2020","unstructured":"Ortega M.A.; Guzm\u00e1n Merino A.; Fraile-Mart\u00ednez O.; Recio-Ruiz J.; Pekarek L.; G Guijarro L.; Garc\u00eda-Honduvilla N.; \u00c1lvarez-Mon M.; Buj\u00e1n J.; Garc\u00eda-Gallego S.; Dendrimers and Dendritic Materials: From Laboratory to Medical Practice in Infectious Diseases. Pharmaceutics  2020,12(9),874","journal-title":"Pharmaceutics"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3390\/biom9120790","volume":"9","author":"Zhu Y.","year":"2019","unstructured":"Zhu Y.; Liu C.; Pang Z.; Dendrimer-Based Drug Delivery Systems for Brain Targeting. Biomolecules  2019,9(12),790","journal-title":"Biomolecules"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.3390\/molecules25173982","volume":"25","author":"Chis A.A.","year":"2020","unstructured":"Chis A.A.; Dobrea C.; Morgovan C.; Arseniu A.M.; Rus L.L.; Butuca A.; Juncan A.M.; Totan M.; Vonica-Tincu A.L.; Cormos G.; Muntean A.C.; Muresan M.L.; Gligor F.G.; Frum A.; Applications and Limitations of Dendrimers in Biomedicine. Molecules  2020,25(17),3982","journal-title":"Molecules"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.parkreldis.2020.10.027","volume":"80","author":"LeWitt P.A.","year":"2020","unstructured":"LeWitt P.A.; Aradi S.D.; Hauser R.A.; Rascol O.; The challenge of developing adenosine A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord  2020,80(Suppl. 1),S54-S63","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1358\/dot.2020.56.2.3098156","volume":"56","author":"Paton D.M.","year":"2020","unstructured":"Paton D.M.; Istradefylline: adenosine A2A receptor antagonist to reduce \u201cOFF\u201d time in Parkinson\u2019s disease. Drugs Today (Barc)  2020,56(2),125-134","journal-title":"Drugs Today (Barc)"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00213-013-3158-x","volume":"230","author":"Kadowaki Horita T.","year":"2013","unstructured":"Kadowaki Horita T.; Kobayashi M.; Mori A.; Jenner P.; Kanda T.; Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology (Berl)  2013,230(3),345-352","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/neurolint12030017","volume":"12","author":"Berger A.A.","year":"2020","unstructured":"Berger A.A.; Winnick A.; Welschmeyer A.; Kaneb A.; Berardino K.; Cornett E.M.; Kaye A.D.; Viswanath O.; Urits I.; Istradefylline to Treat Patients with Parkinson\u2019s Disease Experiencing \u201cOff\u201d Episodes: A Comprehensive Review. Neurol Int  2020,12(3),109-129","journal-title":"Neurol Int"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1212\/01.WNL.0000095213.86899.21","volume":"61","author":"Ascherio A.","year":"2003","unstructured":"Ascherio A.; Chen H.; Caffeinated clues from epidemiology of Parkinson\u2019s disease. Neurology  2003,61(11_suppl_6)(Suppl. 6),S51-S54","journal-title":"Neurology"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"RC143","DOI":"10.1523\/JNEUROSCI.21-10-j0001.2001","volume":"21","author":"Chen J.F.","year":"2001","unstructured":"Chen J.F.; Xu K.; Petzer J.P.; Staal R.; Xu Y.H.; Beilstein M.; Sonsalla P.K.; Castagnoli K.; Castagnoli N.; Schwarzschild M.A.; Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson\u2019s disease. J Neurosci  2001,21(10),RC143","journal-title":"J Neurosci"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0014-4886(03)00250-4","volume":"184","author":"Bibbiani F.","year":"2003","unstructured":"Bibbiani F.; Oh J.D.; Petzer J.P.; Castagnoli N.; Chen J.F.; Schwarzschild M.A.; Chase T.N.; A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson\u2019s disease. Exp Neurol  2003,184(1),285-294","journal-title":"Exp Neurol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.pharmthera.2004.10.007","volume":"105","author":"Xu K.","year":"2005","unstructured":"Xu K.; Bastia E.; Schwarzschild M.; Therapeutic potential of adenosine A2A receptor antagonists in Parkinson\u2019s disease. Pharmacol Ther  2005,105(3),267-310","journal-title":"Pharmacol Ther"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.parkreldis.2020.09.026","volume":"80","author":"Kanda T.","year":"2020","unstructured":"Kanda T.; Jenner P.; Can adenosine A2A receptor antagonists modify motor behavior and dyskinesia in experimental models of Parkinson\u2019s disease? Parkinsonism Relat Disord  2020,80(S1),S21-S27","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/0169-328X(92)90173-9","volume":"14","author":"Fink J.S.","year":"1992","unstructured":"Fink J.S.; Weaver D.R.; Rivkees S.A.; Peterfreund R.A.; Pollack A.E.; Adler E.M.; Reppert S.M.; Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res  1992,14(3),186-195","journal-title":"Brain Res Mol Brain Res"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNF.0000000000000073","volume":"38","author":"Kondo T.","year":"2015","unstructured":"Kondo T.; Mizuno Y.; A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol  2015,38(2),41-46","journal-title":"Clin Neuropharmacol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"18018","DOI":"10.1038\/s41598-017-18339-1","volume":"7","author":"Sako W.","year":"2017","unstructured":"Sako W.; Murakami N.; Motohama K.; Izumi Y.; Kaji R.; The effect of istradefylline for Parkinson\u2019s disease: A meta-analysis. Sci Rep  2017,7(1),18018","journal-title":"Sci Rep"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1080\/14656566.2018.1518433","volume":"19","author":"Takahashi M.","year":"2018","unstructured":"Takahashi M.; Fujita M.; Asai N.; Saki M.; Mori A.; Safety and effectiveness of istradefylline in patients with Parkinson\u2019s disease: interim analysis of a post-marketing surveillance study in Japan. Expert Opin Pharmacother  2018,19(15),1635-1642","journal-title":"Expert Opin Pharmacother"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1212\/WNL.52.8.1673","volume":"52","author":"Grondin R.","year":"1999","unstructured":"Grondin R.; B\u00e9dard P.J.; Tahar A.H.; Gr\u00e9goire L.; Mori A.; Kase H.; Antiparkinsonian effect of a new selective adenosine A  receptor antagonist in MPTP-treated monkeys. Neurology  1999,52(8),1673-1677","journal-title":"Neurology"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.1523\/JNEUROSCI.20-15-05848.2000","volume":"20","author":"Aoyama S.","year":"2000","unstructured":"Aoyama S.; Kase H.; Borrelli E.; Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci  2000,20(15),5848-5852","journal-title":"J Neurosci"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"17124","DOI":"10.1021\/acssuschemeng.8b04507","volume":"6","author":"Wang M.","year":"2018","unstructured":"Wang M.; Li L.; Zhang X.; Liu Y.; Zhu R.; Liu L.; Fang Y.; Gao Z.; Gao D.; Magnetic resveratrol liposomes as a new theranostic platform for magnetic resonance imaging guided Parkinson\u2019s disease targeting therapy. ACS Sustain Chemand Eng  2018,6(12),17124-17133","journal-title":"ACS Sustain Chemand Eng"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00702-018-1848-6","volume":"125","author":"Pinna A.","year":"2018","unstructured":"Pinna A.; Serra M.; Morelli M.; Simola N.; Role of adenosine A receptors in motor control: relevance to Parkinson\u2019s disease and dyskinesia. J Neural Transm (Vienna)  2018,125(8),1273-1286","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1212\/01.WNL.0000095211.71092.A0","volume":"61","author":"Mori A.","year":"2003","unstructured":"Mori A.; Shindou T.; Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology  2003,61(11),S44-S48","journal-title":"Neurology"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.parkreldis.2020.09.025","volume":"80","author":"Mori A.","year":"2020","unstructured":"Mori A.; How do adenosine A receptors regulate motor function? Parkinsonism Relat Disord  2020,80(Suppl. 1),S13-S20","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1517\/13543784.14.6.729","volume":"14","author":"Jenner P.","year":"2005","unstructured":"Jenner P.; Istradefylline, a novel adenosine A receptor antagonist, for the treatment of Parkinson\u2019s disease. Expert Opin Investig Drugs  2005,14(6),729-738","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","volume":"61","author":"Bara-Jimenez W.","year":"2003","unstructured":"Bara-Jimenez W.; Sherzai A.; Dimitrova T.; Favit A.; Bibbiani F.; Gillespie M.; Morris M.J.; Mouradian M.M.; Chase T.N.; Adenosine A.; Adenosine A  receptor antagonist treatment of Parkinson\u2019s disease. Neurology  2003,61(3),293-296","journal-title":"Neurology"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1212\/01.WNL.0000095206.44418.5C","volume":"61","author":"Fuxe K.","year":"2003","unstructured":"Fuxe K.; Agnati L.F.; Jacobsen K.; Hillion J.; Canals M.; Torvinen M.; Tinner-Staines B.; Staines W.; Rosin D.; Terasmaa A.; Popoli P.; Leo G.; Vergoni V.; Lluis C.; Ciruela F.; Franco R.; Ferr\u00e9 S.; Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson\u2019s disease. Neurology  2003,61(11)(Suppl. 6),S19-S23","journal-title":"Neurology"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"10414","DOI":"10.1523\/JNEUROSCI.3660-05.2005","volume":"25","author":"Kachroo A.","year":"2005","unstructured":"Kachroo A.; Orlando L.R.; Grandy D.K.; Chen J.F.; Young A.B.; Schwarzschild M.A.; Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci  2005,25(45),10414-10419","journal-title":"J Neurosci"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/sj.npp.1300444","volume":"29","author":"Coccurello R.","year":"2004","unstructured":"Coccurello R.; Breysse N.; Amalric M.; Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology  2004,29(8),1451-1461","journal-title":"Neuropsychopharmacology"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neuropharm.2004.03.005","volume":"47","author":"More J.C.A.","year":"2004","unstructured":"More J.C.A.; Nistico R.; Dolman N.P.; Clarke V.R.J.; Alt A.J.; Ogden A.M.; Buelens F.P.; Troop H.M.; Kelland E.E.; Pilato F.; Bleakman D.; Bortolotto Z.A.; Collingridge G.L.; Jane D.E.; Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology  2004,47(1),46-64","journal-title":"Neuropharmacology"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejphar.2003.12.023","volume":"486","author":"O\u2019Neill M.J.","year":"2004","unstructured":"O\u2019Neill M.J.; Murray T.K.; Whalley K.; Ward M.A.; Hicks C.A.; Woodhouse S.; Osborne D.J.; Skolnick P.; Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson\u2019s disease. Eur J Pharmacol  2004,486(2),163-174","journal-title":"Eur J Pharmacol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"13668","DOI":"10.1073\/pnas.1835724100","volume":"100","author":"Marino M.J.","year":"2003","unstructured":"Marino M.J.; Williams D.L.; O\u2019Brien J.A.; Valenti O.; McDonald T.P.; Clements M.K.; Wang R.; DiLella A.G.; Hess J.F.; Kinney G.G.; Conn P.J.; Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson\u2019s disease treatment. Proc Natl Acad Sci USA  2003,100(23),13668-13673","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"119","DOI":"10.14581\/jer.19012","volume":"9","author":"Mishra A.","year":"2019","unstructured":"Mishra A.; Goel R.K.; Modulatory Effect of Serotonergic System in Pentylenetetrazole-Induced Seizures and Associated Memory Deficit: Role of 5-HT<sub>1A<\/sub> and 5-HT<sub>2A\/2C<\/sub>. J Epilepsy Res  2019,9(2),119-125","journal-title":"J Epilepsy Res"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.neuroscience.2016.10.010","volume":"339","author":"Mishra A.","year":"2016","unstructured":"Mishra A.; Goel R.K.; Chronic 5-HT receptor antagonism ameliorates seizures and associated memory deficit in pentylenetetrazole-kindled mice. Neuroscience  2016,339(339),319-328","journal-title":"Neuroscience"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","volume":"57","author":"Bibbiani F.","year":"2001","unstructured":"Bibbiani F.; Oh J.D.; Chase T.N.; Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology  2001,57(10),1829-1834","journal-title":"Neurology"},{"key":"ref=152","first-page":"127","volume":"2","author":"Sharifi H.","year":"2012","unstructured":"Sharifi H.; Mohajjel Nayebia A.; Farajnia S.; The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats. Adv Pharm Bull  2012,2(1),127-131","journal-title":"Adv Pharm Bull"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.nbd.2006.02.003","volume":"23","author":"Bezard E.","year":"2006","unstructured":"Bezard E.; Gerlach I.; Moratalla R.; Gross C.E.; Jork R.; 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson\u2019s disease. Neurobiol Dis  2006,23(1),77-86","journal-title":"Neurobiol Dis"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.nbd.2015.11.022","volume":"86","author":"Ghiglieri V.","year":"2016","unstructured":"Ghiglieri V.; Mineo D.; Vannelli A.; Cacace F.; Mancini M.; Pendolino V.; Napolitano F.; di Maio A.; Mellone M.; Stanic J.; Tronci E.; Fidalgo C.; Stancampiano R.; Carta M.; Calabresi P.; Gardoni F.; Usiello A.; Picconi B.; Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms. Neurobiol Dis  2016,86,140-153","journal-title":"Neurobiol Dis"},{"key":"ref=155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.parkreldis.2020.06.026","volume":"77","author":"Clive G.","year":"2020","unstructured":"Clive G.; Ballard, David L. Kreitzman, Stuart Isaacson, I-Yuan Liu, James C. Norton, George Demos, Hubert H. Fernandez, Tihomir V. Ilic, Jean- Philippe Azulay, Joaquim J. Ferreira, Victor Abler, Srdjan Stankovic, 015 Study Group. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson\u2019s disease psychosis. Parkinsonism Relat Disord  2020,77,100-106","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neuropharm.2018.06.038","volume":"139","author":"Hamadjida A.","year":"2018","unstructured":"Hamadjida A.; Nuara S.G.; B\u00e9dard D.; Gaudette F.; Beaudry F.; Gourdon J.C.; Huot P.; The highly selective 5-HT antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset. Neuropharmacology  2018,139(139),61-67","journal-title":"Neuropharmacology"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.pneurobio.2016.07.002","volume":"151","author":"De Deurwaerd\u00e8re P.","year":"2017","unstructured":"De Deurwaerd\u00e8re P.; Di Giovanni G.; Millan M.J.; Expanding the repertoire of L-DOPA\u2019s actions: A comprehensive review of its functional neurochemistry. Prog Neurobiol  2017,151,57-100","journal-title":"Prog Neurobiol"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1172\/JCI71640","volume":"124","author":"Politis M.","year":"2014","unstructured":"Politis M.; Wu K.; Loane C.; Brooks D.J.; Kiferle L.; Turkheimer F.E.; Bain P.; Molloy S.; Piccini P.; Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson\u2019s disease patients. J Clin Invest  2014,124(3),1340-1349","journal-title":"J Clin Invest"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"Carta M.","year":"2007","unstructured":"Carta M.; Carlsson T.; Kirik D.; Bj\u00f6rklund A.; Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain  2007,130(7),1819-1833","journal-title":"Brain"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/brain\/awu409","volume":"138","author":"Svenningsson P.","year":"2015","unstructured":"Svenningsson P.; Rosenblad C.; af Edholm Arvidsson K.; Wictorin K.; Keywood C.; Shankar B.; Lowe D.A.; Bj\u00f6rklund A.; Widner H.; Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson\u2019s disease: a dose-finding study. Brain  2015,138(4),963-973","journal-title":"Brain"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1017\/S1461145704005000","volume":"8","author":"Newman-Tancredi A.","year":"2005","unstructured":"Newman-Tancredi A.; Assi\u00e9 M.B.; Leduc N.; Ormi\u00e8re A.M.; Danty N.; Cosi C.; Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol  2005,8(3),341-356","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","volume":"15","author":"Gr\u00e9goire L.","year":"2009","unstructured":"Gr\u00e9goire L.; Samadi P.; Graham J.; B\u00e9dard P.J.; Bartoszyk G.D.; Di Paolo T.; Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord  2009,15(6),445-452","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.bbrc.2006.01.057","volume":"341","author":"Hayashita-Kinoh H.","year":"2006","unstructured":"Hayashita-Kinoh H.; Yamada M.; Yokota T.; Mizuno Y.; Mochizuki H.; Down-regulation of \u03b1-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson\u2019s disease rat model. Biochem Biophys Res Commun  2006,341(4),1088-1095","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1750-1326-3-19","volume":"3","author":"Lewis J.","year":"2008","unstructured":"Lewis J.; Melrose H.; Bumcrot D.; Hope A.; Zehr C.; Lincoln S.; Braithwaite A.; He Z.; Ogholikhan S.; Hinkle K.; Kent C.; Toudjarska I.; Charisse K.; Braich R.; Pandey R.K.; Heckman M.; Maraganore D.M.; Crook J.; Farrer M.J.; in vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener  2008,3(1),19","journal-title":"Mol Neurodegener"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/mt.2010.115","volume":"18","author":"Gorbatyuk O.S.","year":"2010","unstructured":"Gorbatyuk O.S.; Li S.; Nash K.; Gorbatyuk M.; Lewin A.S.; Sullivan L.F.; Mandel R.J.; Chen W.; Meyers C.; Manfredsson F.P.; Muzyczka N.; in vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther  2010,18(8),1450-1457","journal-title":"Mol Ther"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"e12122","DOI":"10.1371\/journal.pone.0012122","volume":"5","author":"McCormack A.L.","year":"2010","unstructured":"McCormack A.L.; Mak S.K.; Henderson J.M.; Bumcrot D.; Farrer M.J.; Di Monte D.A.; Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One  2010,5(8),e12122","journal-title":"PLoS One"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.brainres.2014.01.010","volume":"1550","author":"Khodr C.E.","year":"2014","unstructured":"Khodr C.E.; Becerra A.; Han Y.; Bohn M.C.; Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: Positive and negative effects. Brain Res  2014,1550(1550),47-60","journal-title":"Brain Res"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/mds.25978","volume":"29","author":"Cooper J.M.","year":"2014","unstructured":"Cooper J.M.; Wiklander P.B.O.; Nordin J.Z.; Al-Shawi R.; Wood M.J.; Vithlani M.; Schapira A.H.V.; Simons J.P.; El-Andaloussi S.; Alvarez-Erviti L.; Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord  2014,29(12),1476-1485","journal-title":"Mov Disord"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1172\/JCI64502","volume":"125","author":"Zharikov A.D.","year":"2015","unstructured":"Zharikov A.D.; Cannon J.R.; Tapias V.; Bai Q.; Horowitz M.P.; Shah V.; El Ayadi A.; Hastings T.G.; Greenamyre J.T.; Burton E.A.; shRNA targeting \u03b1-synuclein prevents neurodegeneration in a Parkinson\u2019s disease model. J Clin Invest  2015,125(7),2721-2735","journal-title":"J Clin Invest"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omtn.2017.08.013","volume":"9","author":"Helmschrodt C.","year":"2017","unstructured":"Helmschrodt C.; H\u00f6bel S.; Sch\u00f6niger S.; Bauer A.; Bonicelli J.; Gringmuth M.; Fietz S.A.; Aigner A.; Richter A.; Richter F.; Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce \u03b1-Synuclein Expression in a Model of Parkinson\u2019s Disease. Mol Ther Nucleic Acids  2017,9(9),57-68","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","volume":"87","author":"Evers M.M.","year":"2015","unstructured":"Evers M.M.; Toonen L.J.A.; van Roon-Mom W.M.C.; Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev  2015,87(87),90-103","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature11362","volume":"488","author":"Wheeler T.M.","year":"2012","unstructured":"Wheeler T.M.; Leger A.J.; Pandey S.K.; MacLeod A.R.; Nakamori M.; Cheng S.H.; Wentworth B.M.; Bennett C.F.; Thornton C.A.; Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature  2012,488(7409),111-115","journal-title":"Nature"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1039\/C5OB00242G","volume":"13","author":"Yamamoto T.","year":"2015","unstructured":"Yamamoto T.; Yahara A.; Waki R.; Yasuhara H.; Wada F.; Harada-Shiba M.; Obika S.; Amido-bridged nucleic acids with small hydrophobic residues enhance hepatic tropism of antisense oligonucleotides in vivo. Org Biomol Chem  2015,13(12),3757-3765","journal-title":"Org Biomol Chem"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"102793","DOI":"10.1016\/j.jddst.2021.102793","volume":"66","author":"Shankar J.","year":"2021","unstructured":"Shankar J.; Geetha K.M.; Barnabas Wilson, Potential applications of nanomedicine for treating Parkinson\u2019s disease. J Drug Deliv Sci Technol  2021,66,102793","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"112117","DOI":"10.1016\/j.biopha.2021.112117","volume":"143","author":"Nguyen T.T.","year":"2021","unstructured":"Nguyen T.T.; Dung Nguyen T.T.; Vo T.K.; Tran N.M.A.; Nguyen M.K.; Van Vo T.; Van Vo G.; Nanotechnology-based drug delivery for central nervous system disorders. Biomed Pharmacother  2021,143,112117","journal-title":"Biomed Pharmacother"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3390\/molecules25081929","volume":"25","author":"Islam S.U.","year":"2020","unstructured":"Islam S.U.; Shehzad A.; Ahmed M.B.; Lee Y.S.; Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders. Molecules  2020,25(8),1929","journal-title":"Molecules"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"a009431","DOI":"10.1101\/cshperspect.a009431","volume":"2","author":"Coune P.G.","year":"2012","unstructured":"Coune P.G.; Schneider B.L.; Aebischer P.; Parkinson\u2019s disease: gene therapies. Cold Spring Harb Perspect Med  2012,2(4),a009431","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/mt.2013.285","volume":"22","author":"Borel F.","year":"2014","unstructured":"Borel F.; Kay M.A.; Mueller C.; Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther  2014,22(4),692-701","journal-title":"Mol Ther"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omtm.2019.11.012","volume":"17","author":"Haggerty D.L.","year":"2020","unstructured":"Haggerty D.L.; Grecco G.G.; Reeves K.C.; Atwood B.; Adeno-Associated Viral Vectors in Neuroscience Research. Mol Ther Methods Clin Dev  2020,17,69-82","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.biotechadv.2018.11.009","volume":"37","author":"Han H.","year":"2019","unstructured":"Han H.; Yang J.; Chen W.; Li Q.; Yang Y.; Li Q.; A comprehensive review on histone-mediated transfection for gene therapy. Biotechnol Adv  2019,37(1),132-144","journal-title":"Biotechnol Adv"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","volume":"101","author":"Hudry E.","year":"2019","unstructured":"Hudry E.; Vandenberghe L.H.; Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron  2019,101(5),839-862","journal-title":"Neuron"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","volume":"14","author":"Wu Z.","year":"2006","unstructured":"Wu Z.; Asokan A.; Samulski R.J.; Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther  2006,14(3),316-327","journal-title":"Mol Ther"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/hum.2006.17.1","volume":"17","author":"Wong L.F.","year":"2006","unstructured":"Wong L.F.; Goodhead L.; Prat C.; Mitrophanous K.A.; Kingsman S.M.; Mazarakis N.D.; Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. Hum Gene Ther  2006,17(1),1-9","journal-title":"Hum Gene Ther"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3233\/JPD-181331","volume":"8","author":"Axelsen T.M.","year":"2018","unstructured":"Axelsen T.M.; Woldbye D.P.D.; Gene therapy for Parkinson\u2019s disease, an update. J Parkinsons Dis  2018,8(2),195-215","journal-title":"J Parkinsons Dis"},{"key":"ref=185","first-page":"519","volume":"12","author":"Fiandaca M.S.","year":"2010","unstructured":"Fiandaca M.S.; Bankiewicz K.S.; Gene therapy for Parkinson\u2019s disease: from non-human primates to humans. Curr Opin Mol Ther  2010,12(5),519-529","journal-title":"Curr Opin Mol Ther"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"9928","DOI":"10.1523\/JNEUROSCI.2185-07.2007","volume":"27","author":"Cearley C.N.","year":"2007","unstructured":"Cearley C.N.; Wolfe J.H.; A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci  2007,27(37),9928-9940","journal-title":"J Neurosci"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"T27","DOI":"10.1016\/j.neuroimage.2008.11.012","volume":"47","author":"Fiandaca M.S.","year":"2009","unstructured":"Fiandaca M.S.; Varenika V.; Eberling J.; McKnight T.; Bringas J.; Pivirotto P.; Beyer J.; Hadaczek P.; Bowers W.; Park J.; Federoff H.; Forsayeth J.; Bankiewicz K.S.; Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage  2009,47(Suppl 2)(Suppl. 2),T27-T35","journal-title":"Neuroimage"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.omtm.2019.10.007","volume":"15","author":"Hanlon K.S.","year":"2019","unstructured":"Hanlon K.S.; Meltzer J.C.; Buzhdygan T.; Cheng M.J.; Sena-Esteves M.; Bennett R.E.; Sullivan T.P.; Razmpour R.; Gong Y.; Ng C.; Nammour J.; Maiz D.; Dujardin S.; Ramirez S.H.; Hudry E.; Maguire C.A.; Selection of an efficient AAV vector for robust CNS transgene expression. Mol Ther Methods Clin Dev  2019,15,320-332","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"16026","DOI":"10.1038\/mtm.2016.26","volume":"3","author":"Rosario A.M.","year":"2016","unstructured":"Rosario A.M.; Cruz P.E.; Ceballos-Diaz C.; Strickland M.R.; Siemienski Z.; Pardo M.; Schob K.L.; Li A.; Aslanidi G.V.; Srivastava A.; Golde T.E.; Chakrabarty P.; Microglia-specific targeting by novel capsid-modified AAV6 vectors. Mol Ther Methods Clin Dev  2016,3,16026","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.25450","volume":"85","author":"Christine C.W.","year":"2019","unstructured":"Christine C.W.; Bankiewicz K.S.; Van Laar A.D.; Richardson R.M.; Ravina B.; Kells A.P.; Boot B.; Martin A.J.; Nutt J.; Thompson M.E.; Larson P.S.; Magnetic resonance imaging\u2013guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease. Ann Neurol  2019,85(5),704-714","journal-title":"Ann Neurol"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1089\/hum.2017.048","volume":"28","author":"Berns K.I.","year":"2017","unstructured":"Berns K.I.; Muzyczka N.; AAV: an overview of unanswered questions. Hum Gene Ther  2017,28(4),308-313","journal-title":"Hum Gene Ther"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/1566523054065057","volume":"5","author":"Gao G.","year":"2005","unstructured":"Gao G.; Vandenberghe L.; Wilson J.; New recombinant serotypes of AAV vectors. Curr Gene Ther  2005,5(3),285-297","journal-title":"Curr Gene Ther"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/B978-0-12-800149-3.00003-2","volume":"87","author":"Kantor B.","year":"2014","unstructured":"Kantor B.; Bailey R.M.; Wimberly K.; Kalburgi S.N.; Gray S.J.; Methods for gene transfer to the central nervous system. Adv Genet  2014,87,125-197","journal-title":"Adv Genet"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/mt.2008.171","volume":"16","author":"McCarty D.M.","year":"2008","unstructured":"McCarty D.M.; Self-complementary AAV vectors; advances and applications. Mol Ther  2008,16(10),1648-1656","journal-title":"Mol Ther"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/mt.2009.71","volume":"17","author":"Duque S.","year":"2009","unstructured":"Duque S.; Joussemet B.; Riviere C.; Marais T.; Dubreil L.; Douar A.M.; Fyfe J.; Moullier P.; Colle M.A.; Barkats M.; Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther  2009,17(7),1187-1196","journal-title":"Mol Ther"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/hmg\/ddq514","volume":"20","author":"Dominguez E.","year":"2011","unstructured":"Dominguez E.; Marais T.; Chatauret N.; Benkhelifa-Ziyyat S.; Duque S.; Ravassard P.; Carcenac R.; Astord S.; de Moura A.P.; Voit T.; Barkats M.; Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet  2011,20(4),681-693","journal-title":"Hum Mol Genet"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","volume":"28","author":"Foust K.D.","year":"2010","unstructured":"Foust K.D.; Wang X.; McGovern V.L.; Braun L.; Bevan A.K.; Haidet A.M.; Le T.T.; Morales P.R.; Rich M.M.; Burghes A.H.M.; Kaspar B.K.; RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol  2010,28(3),271-274","journal-title":"Nat Biotechnol"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","volume":"2","author":"Valori C.F.","year":"2010","unstructured":"Valori C.F.; Ning K.; Wyles M.; Mead R.J.; Grierson A.J.; Shaw P.J.; Azzouz M.; Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med  2010,2(35),35ra42","journal-title":"Sci Transl Med"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2174\/1566523054546224","volume":"5","author":"Cronin J.","year":"2005","unstructured":"Cronin J.; Zhang X.Y.; Reiser J.; Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther  2005,5(4),387-398","journal-title":"Curr Gene Ther"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","volume":"72","author":"Dull T.","year":"1998","unstructured":"Dull T.; Zufferey R.; Kelly M.; Mandel R.J.; Nguyen M.; Trono D.; Naldini L.; A third-generation lentivirus vector with a conditional packaging system. J Virol  1998,72(11),8463-8471","journal-title":"J Virol"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.272.5259.263","volume":"272","author":"Naldini L.","year":"1996","unstructured":"Naldini L.; Bl\u00f6mer U.; Gallay P.; Ory D.; Mulligan R.; Gage F.H.; Verma I.M.; Trono D.; in vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science  1996,272(5259),263-267","journal-title":"Science"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/sj.gt.3300768","volume":"5","author":"Olsen J.C.","year":"1998","unstructured":"Olsen J.C.; Gene transfer vectors derived from equine infectious anemia virus. Gene Ther  1998,5(11),1481-1487","journal-title":"Gene Ther"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","volume":"72","author":"Zufferey R.","year":"1998","unstructured":"Zufferey R.; Dull T.; Mandel R.J.; Bukovsky A.; Quiroz D.; Naldini L.; Trono D.; Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol  1998,72(12),9873-9880","journal-title":"J Virol"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nbt0997-871","volume":"15","author":"Zufferey R.","year":"1997","unstructured":"Zufferey R.; Nagy D.; Mandel R.J.; Naldini L.; Trono D.; Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol  1997,15(9),871-875","journal-title":"Nat Biotechnol"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14737175.2020.1763794","volume":"20","author":"Merola A.","year":"2020","unstructured":"Merola A.; Van Laar A.; Lonser R.; Bankiewicz K.; Gene therapy for Parkinson\u2019s disease: contemporary practice and emerging concepts. Expert Rev Neurother  2020,20(6),577-590","journal-title":"Expert Rev Neurother"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.nbd.2016.07.009","volume":"97","author":"Lindahl M.","year":"2017","unstructured":"Lindahl M.; Saarma M.; Lindholm P.; Unconventional neurotrophic factors CDNF and MANF: structure, physiological functions and therapeutic potential. Neurobiol Dis  2017,97(Pt B),90-102","journal-title":"Neurobiol Dis"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/mds.26049","volume":"30","author":"Jahanshahi M.","year":"2015","unstructured":"Jahanshahi M.; Obeso I.; Baunez C.; Alegre M.; Krack P.; Parkinson\u2019s  isease, the  ubthalamic  ucleus,  nhibition, and  mpulsivity. Mov Disord  2015,30(2),128-140","journal-title":"Mov Disord"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0896-6273(91)90077-D","volume":"7","author":"Erlander M.G.","year":"1991","unstructured":"Erlander M.G.; Tillakaratne N.J.K.; Feldblum S.; Patel N.; Tobin A.J.; Two genes encode distinct glutamate decarboxylases. Neuron  1991,7(1),91-100","journal-title":"Neuron"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s12272-019-01196-z","volume":"42","author":"Lee S.E.","year":"2019","unstructured":"Lee S.E.; Lee Y.; Lee G.H.; The regulation of glutamic acid decarboxylases in GABA neurotransmission in the brain. Arch Pharm Res  2019,42(12),1031-1039","journal-title":"Arch Pharm Res"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"Kaplitt M.G.","year":"2007","unstructured":"Kaplitt M.G.; Feigin A.; Tang C.; Fitzsimons H.L.; Mattis P.; Lawlor P.A.; Bland R.J.; Young D.; Strybing K.; Eidelberg D.; During M.J.; Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial. Lancet  2007,369(9579),2097-2105","journal-title":"Lancet"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"LeWitt P.A.","year":"2011","unstructured":"LeWitt P.A.; Rezai A.R.; Leehey M.A.; Ojemann S.G.; Flaherty A.W.; Eskandar E.N.; Kostyk S.K.; Thomas K.; Sarkar A.; Siddiqui M.S.; Tatter S.B.; Schwalb J.M.; Poston K.L.; Henderson J.M.; Kurlan R.M.; Richard I.H.; Van Meter L.; Sapan C.V.; During M.J.; Kaplitt M.G.; Feigin A.; AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham- surgery controlled, randomised trial. Lancet Neurol  2011,10(4),309-319","journal-title":"Lancet Neurol"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"e90133","DOI":"10.1172\/jci.insight.90133","volume":"2","author":"Niethammer M.","year":"2017","unstructured":"Niethammer M.; Tang C.C.; LeWitt P.A.; Long-term follow-up of a randomized AAV2-. JCI Insight  2017,2(7),e90133","journal-title":"JCI Insight"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"eaau0713","DOI":"10.1126\/scitranslmed.aau0713","volume":"10","author":"Niethammer M.","year":"2018","unstructured":"Niethammer M.; Tang C.C.; Vo A.; Nguyen N.; Spetsieris P.; Dhawan V.; Ma Y.; Small M.; Feigin A.; During M.J.; Kaplitt M.G.; Eidelberg D.; Gene therapy reduces Parkinson\u2019s disease symptoms by reorganizing functional brain connectivity. Sci Transl Med  2018,10(469),eaau0713","journal-title":"Sci Transl Med"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/jnc.14810","volume":"150","author":"Sulzer D.","year":"2019","unstructured":"Sulzer D.; Edwards R.H.; The physiological role of \u03b1-synuclein and its relationship to Parkinson\u2019s Disease. J Neurochem  2019,150(5),475-486","journal-title":"J Neurochem"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"Spillantini M.G.","year":"1997","unstructured":"Spillantini M.G.; Schmidt M.L.; Lee V.M.Y.; Trojanowski J.Q.; Jakes R.; Goedert M.; \u03b1-Synuclein in Lewy bodies. Nature  1997,388(6645),839-840","journal-title":"Nature"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.1523\/JNEUROSCI.6119-09.2010","volume":"30","author":"Jowaed A.","year":"2010","unstructured":"Jowaed A.; Schmitt I.; Kaut O.; W\u00fcllner U.; Methylation regulates alpha-synuclein expression and is decreased in Parkinson\u2019s disease patients\u2019 brains. J Neurosci  2010,30(18),6355-6359","journal-title":"J Neurosci"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","volume":"26","author":"Kantor B.","year":"2018","unstructured":"Kantor B.; Tagliafierro L.; Gu J.; Zamora M.E.; Ilich E.; Grenier C.; Huang Z.Y.; Murphy S.; Chiba-Falek O.; Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD. Mol Ther  2018,26(11),2638-2649","journal-title":"Mol Ther"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"Wagner J.","year":"2013","unstructured":"Wagner J.; Ryazanov S.; Leonov A.; Levin J.; Shi S.; Schmidt F.; Prix C.; Pan-Montojo F.; Bertsch U.; Mitteregger-Kretzschmar G.; Geissen M.; Eiden M.; Leidel F.; Hirschberger T.; Deeg A.A.; Krauth J.J.; Zinth W.; Tavan P.; Pilger J.; Zweckstetter M.; Frank T.; B\u00e4hr M.; Weishaupt J.H.; Uhr M.; Urlaub H.; Teichmann U.; Samwer M.; B\u00f6tzel K.; Groschup M.; Kretzschmar H.; Griesinger C.; Giese A.; Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol  2013,125(6),795-813","journal-title":"Acta Neuropathol"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-3-030-40204-4_4","volume":"1243","author":"Sinnige T.","year":"2020","unstructured":"Sinnige T.; Yu A.; Morimoto R.I.; Challenging proteostasis: role of the chaperone network to control aggregation-prone proteins in human disease. Adv Exp Med Biol  2020,1243,53-68","journal-title":"Adv Exp Med Biol"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3389\/fnmol.2017.00447","volume":"10","author":"Schwab K.","year":"2018","unstructured":"Schwab K.; Frahm S.; Horsley D.; Rickard J.E.; Melis V.; Goatman E.A.; Magbagbeolu M.; Douglas M.; Leith M.G.; Baddeley T.C.; Storey J.M.D.; Riedel G.; Wischik C.M.; Harrington C.R.; Theuring F.; A protein aggregation inhibitor, leuco-methylthioninium bis(hydromethanesulfonate), decreases alpha-synu-clein inclusions in a transgenic mouse model of synucleinopathy. Front Mol Neurosci  2018,10,447","journal-title":"Front Mol Neurosci"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1093\/brain\/aww238","volume":"139","author":"Wrasidlo W.","year":"2016","unstructured":"Wrasidlo W.; Tsigelny I.F.; Price D.L.; Dutta G.; Rockenstein E.; Schwarz T.C.; Ledolter K.; Bonhaus D.; Paulino A.; Eleuteri S.; Skjevik \u00c5.A.; Kouznetsova V.L.; Spencer B.; Desplats P.; Gonzalez-Ruelas T.; Trejo-Morales M.; Overk C.R.; Winter S.; Zhu C.; Chesselet M.F.; Meier D.; Moessler H.; Konrat R.; Masliah E.; A de novo compound targeting \u03b1-synuclein improves deficits in models of Parkinson\u2019s disease. Brain  2016,139(12),3217-3236","journal-title":"Brain"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1038\/s41467-020-18689-x","volume":"11","author":"Bengoa-Vergniory N.","year":"2020","unstructured":"Bengoa-Vergniory N.; Faggiani E.; Ramos-Gonzalez P.; Kirkiz E.; Connor-Robson N.; Brown L.V.; Siddique I.; Li Z.; Vingill S.; Cioroch M.; Cavaliere F.; Threlfell S.; Roberts B.; Schrader T.; Kl\u00e4rner F.G.; Cragg S.; Dehay B.; Bitan G.; Matute C.; Bezard E.; Wade-Martins R.; CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson\u2019s disease. Nat Commun  2020,11(1),4885","journal-title":"Nat Commun"},{"key":"ref=223","first-page":"e204725","volume":"2020","author":"Simuni T.","year":"2020","unstructured":"Simuni T.; Fiske B.; Merchant K.; Coffey C.S.; Klingner E.; Caspell-Garcia C.; Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol  2020,2020,e204725","journal-title":"JAMA Neurol"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","volume":"77","author":"Pagan F.L.","year":"2020","unstructured":"Pagan F.L.; Hebron M.L.; Wilmarth B.; Torres-Yaghi Y.; Lawler A.; Mundel E.E.; Yusuf N.; Starr N.J.; Anjum M.; Arellano J.; Howard H.H.; Shi W.; Mulki S.; Kurd-Misto T.; Matar S.; Liu X.; Ahn J.; Moussa C.; Nilotinib effects on safety, tolerability, and potential biomarkers in parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol  2020,77(3),309-317","journal-title":"JAMA Neurol"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1001\/jamaneurol.2019.3983","volume":"77","author":"Espay A.J.","year":"2020","unstructured":"Espay A.J.; Hauser R.A.; Armstrong M.J.; The narrowing path for nilotinib and other potential disease-modifying therapies for parkinson disease. JAMA Neurol  2020,77(3),295-297","journal-title":"JAMA Neurol"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","volume":"19","author":"Volc D.","year":"2020","unstructured":"Volc D.; Poewe W.; Kutzelnigg A.; L\u00fchrs P.; Thun-Hohenstein C.; Schneeberger A.; Galabova G.; Majbour N.; Vaikath N.; El-Agnaf O.; Winter D.; Mihailovska E.; Mairhofer A.; Schwenke C.; Staffler G.; Medori R.; Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol  2020,19(7),591-600","journal-title":"Lancet Neurol"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","volume":"11","author":"Pardridge W.M.","year":"2020","unstructured":"Pardridge W.M.; Blood-brain barrier and delivery of protein and gene therapeutics to brain. Front Aging Neurosci  2020,11,373","journal-title":"Front Aging Neurosci"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"18688","DOI":"10.1038\/s41598-019-55091-0","volume":"9","author":"Gaston J.","year":"2019","unstructured":"Gaston J.; Maestrali N.; Lalle G.; Gagnaire M.; Masiero A.; Dumas B.; Dabdoubi T.; Rado\u0161evi\u0107 K.; Berne P.F.; Intracellular delivery of therapeutic antibodies into specific cells using antibody-peptide fusions. Sci Rep  2019,9(1),18688","journal-title":"Sci Rep"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"Jankovic J.","year":"2018","unstructured":"Jankovic J.; Goodman I.; Safirstein B.; Marmon T.K.; Schenk D.B.; Koller M.; Zago W.; Ness D.K.; Griffith S.G.; Grundman M.; Soto J.; Ostrowitzki S.; Boess F.G.; Martin-Facklam M.; Quinn J.F.; Isaacson S.H.; Omidvar O.; Ellenbogen A.; Kinney G.G.; Safety and Tolerability of Multiple Ascending Doses of PRX002\/RG7935, an Anti\u2013\u03b1-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease. JAMA Neurol  2018,75(10),1206-1214","journal-title":"JAMA Neurol"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11302-008-9100-8","volume":"4","author":"Cie\u015blak M.","year":"2008","unstructured":"Cie\u015blak M.; Komoszy\u0144ski M.; Wojtczak A.; Adenosine A2A receptors in Parkinson\u2019s disease treatment. Purinergic Signal  2008,4(4),305-312","journal-title":"Purinergic Signal"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1021\/acschemneuro.8b00313","volume":"10","author":"Zheng J.","year":"2019","unstructured":"Zheng J.; Zhang X.; Zhen X.; Development of adenosine A. ACS Chem Neurosci  2019,10(2),783-791","journal-title":"ACS Chem Neurosci"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/jnc.13885","volume":"140","author":"Cervetto C.","year":"2017","unstructured":"Cervetto C.; Venturini A.; Passalacqua M.; Guidolin D.; Genedani S.; Fuxe K.; Borroto-Esquela D.O.; Cortelli P.; Woods A.; Maura G.; Marcoli M.; Agnati L.F.; A2A-D2 receptor\u2013receptor interaction modulates gliotransmitter release from striatal astrocyte processes. J Neurochem  2017,140(2),268-279","journal-title":"J Neurochem"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fnins.2018.00043","volume":"12","author":"Borroto-Escuela D.O.","year":"2018","unstructured":"Borroto-Escuela D.O.; Hinz S.; Navarro G.; Franco R.; M\u00fcller C.E.; Fuxe K.; Understanding the role of adenosine A2AR heteroreceptor complexes in neurodegeneration and neuroinflammation. Front Neurosci  2018,12,43","journal-title":"Front Neurosci"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/6975841","volume":"2017","author":"Vuorimaa A.","year":"2017","unstructured":"Vuorimaa A.; Rissanen E.; Airas L.; PET imaging of adenosine 2A receptors in neuroinflammatory and neurodegenerative disease. Contrast Media Mol Imaging  2017,2017,1-15","journal-title":"Contrast Media Mol Imaging"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1469-7793.2001.0423f.x","volume":"532","author":"Shindou T.","year":"2001","unstructured":"Shindou T.; Mori A.; Kase H.; Ichimura M.; Adenosine A  receptor enhances GABA  -mediated IPSCs in the rat globus pallidus. J Physiol  2001,532(2),423-434","journal-title":"J Physiol"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/sj.bjp.0704702","volume":"136","author":"Shindou T.","year":"2002","unstructured":"Shindou T.; Nonaka H.; Richardson P.J.; Mori A.; Kase H.; Ichimura M.; Presynaptic adenosine A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus. Br J Pharmacol  2002,136(2),296-302","journal-title":"Br J Pharmacol"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neulet.2003.08.059","volume":"352","author":"Shindou T.","year":"2003","unstructured":"Shindou T.; Richardson P.J.; Mori A.; Kase H.; Ichimura M.; Adenosine modulates the striatal GABAergic inputs to the globus pallidus via adenosine A2A receptors in rats. Neurosci Lett  2003,352(3),167-170","journal-title":"Neurosci Lett"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/jnc.13652","volume":"138","author":"Beggiato S.","year":"2016","unstructured":"Beggiato S.; Tomasini M.C.; Borelli A.C.; Borroto-Escuela D.O.; Fuxe K.; Antonelli T.; Tanganelli S.; Ferraro L.; Functional role of striatal A2A, D2, and  lu5 receptor interactions in regulating striatopallidal  neuronal transmission. J Neurochem  2016,138(2),254-264","journal-title":"J Neurochem"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s12264-020-00582-8","volume":"36","author":"Glaser T.","year":"2020","unstructured":"Glaser T.; Andrejew R.; Oliveira-Giacomelli \u00c1.; Ribeiro D.E.; Bonfim Marques L.; Ye Q.; Ren W.J.; Semyanov A.; Illes P.; Tang Y.; Ulrich H.; Purinergic receptors in basal ganglia diseases: shared molecular mechanisms between Huntington\u2019s and Parkinson\u2019s Disease. Neurosci Bull  2020,36(11),1299-1314","journal-title":"Neurosci Bull"},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1471-4159.2004.02887.x","volume":"92","author":"Rodrigues R.J.","year":"2005","unstructured":"Rodrigues R.J.; Alfaro T.M.; Rebola N.; Oliveira C.R.; Cunha R.A.; Co-localization and functional interaction between adenosine A  and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J Neurochem  2005,92(3),433-441","journal-title":"J Neurochem"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","volume":"16","author":"Chen J.F.","year":"2020","unstructured":"Chen J.F.; Cunha R.A.; The belated US FDA approval of the adenosine A receptor antagonist istradefylline for treatment of Parkinson\u2019s disease. Purinergic Signal  2020,16(2),167-174","journal-title":"Purinergic Signal"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"e17338","DOI":"10.1371\/journal.pone.0017338","volume":"6","author":"Mishina M.","year":"2011","unstructured":"Mishina M.; Ishiwata K.; Naganawa M.; Kimura Y.; Kitamura S.; Suzuki M.; Hashimoto M.; Ishibashi K.; Oda K.; Sakata M.; Hamamoto M.; Kobayashi S.; Katayama Y.; Ishii K.; Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson\u2019s disease patients. PLoS One  2011,6(2),e17338","journal-title":"PLoS One"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.neuropharm.2018.09.036","volume":"143","author":"Ishibashi K.","year":"2018","unstructured":"Ishibashi K.; Miura Y.; Wagatsuma K.; Toyohara J.; Ishiwata K.; Ishii K.; Occupancy of adenosine A receptors by istradefylline in patients with Parkinson\u2019s disease using C-preladenant PET. Neuropharmacology  2018,143,106-112","journal-title":"Neuropharmacology"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/mds.25395","volume":"28","author":"Factor S.A.","year":"2013","unstructured":"Factor S.A.; Wolski K.; Togasaki D.M.; Huyck S.; Cantillon M.; Ho T.W.; Hauser R.A.; Pourcher E.; Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson\u2019s disease. Mov Disord  2013,28(6),817-820","journal-title":"Mov Disord"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S1474-4422(11)70012-6","volume":"10","author":"Hauser R.A.","year":"2011","unstructured":"Hauser R.A.; Cantillon M.; Pourcher E.; Micheli F.; Mok V.; Onofrj M.; Huyck S.; Wolski K.; Preladenant in patients with Parkinson\u2019s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol  2011,10(3),221-229","journal-title":"Lancet Neurol"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1212\/WNL.0000000000004003","volume":"88","author":"Stocchi F.","year":"2017","unstructured":"Stocchi F.; Rascol O.; Hauser R.A.; Huyck S.; Tzontcheva A.; Capece R.; Ho T.W.; Sklar P.; Lines C.; Michelson D.; Hewitt D.J.; Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. Neurology  2017,88(23),2198-2206","journal-title":"Neurology"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1001\/jamaneurol.2015.2268","volume":"72","author":"Hauser R.A.","year":"2015","unstructured":"Hauser R.A.; Stocchi F.; Rascol O.; Huyck S.B.; Capece R.; Ho T.W.; Sklar P.; Lines C.; Michelson D.; Hewitt D.; Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned. JAMA Neurol  2015,72(12),1491-1500","journal-title":"JAMA Neurol"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S1474-4422(14)70148-6","volume":"13","author":"Hauser R.A.","year":"2014","unstructured":"Hauser R.A.; Olanow C.W.; Kieburtz K.D.; Pourcher E.; Docu-Axelerad A.; Lew M.; Kozyolkin O.; Neale A.; Resburg C.; Meya U.; Kenney C.; Bandak S.; Tozadenant (SYN115) in patients with Parkinson\u2019s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol  2014,13(8),767-776","journal-title":"Lancet Neurol"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/WNF.0b013e3181d137d2","volume":"33","author":"Brooks D.J.","year":"2010","unstructured":"Brooks D.J.; Papapetropoulos S.; Vandenhende F.; Tomic D.; He P.; Coppell A.; O\u2019Neill G.; An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. Clin Neuropharmacol  2010,33(2),55-60","journal-title":"Clin Neuropharmacol"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/mp.2011.101","volume":"17","author":"Amin N.","year":"2012","unstructured":"Amin N.; Byrne E.; Johnson J.; Chenevix-Trench G.; Walter S.; Nolte I.M.; Vink J.M.; Rawal R.; Mangino M.; Teumer A.; Keers J.C.; Verwoert G.; Baumeister S.; Biffar R.; Petersmann A.; Dahmen N.; Doering A.; Isaacs A.; Broer L.; Wray N.R.; Montgomery G.W.; Levy D.; Psaty B.M.; Gudnason V.; Chakravarti A.; Sulem P.; Gudbjartsson D.F.; Kiemeney L.A.; Thorsteinsdottir U.; Stefansson K.; van Rooij F.J.A.; Aulchenko Y.S.; Hottenga J.J.; Rivadeneira F.R.; Hofman A.; Uitterlinden A.G.; Hammond C.J.; Shin S-Y.; Ikram A.; Witteman J.C.M.; Janssens A.C.J.W.; Snieder H.; Tiemeier H.; Wolfenbuttel B.H.R.; Oostra B.A.; Heath A.C.; Wichmann E.; Spector T.D.; Grabe H.J.; Boomsma D.I.; Martin N.G.; van Duijn C.M.; Genome-wide association analysis of coffee drinking suggests association with CYP1A1\/CYP1A2 and NRCAM. Mol Psychiatry  2012,17(11),1116-1129","journal-title":"Mol Psychiatry"},{"key":"ref=251","doi-asserted-by":"publisher","first-page":"e1002237","DOI":"10.1371\/journal.pgen.1002237","volume":"7","author":"Hamza T.H.","year":"2011","unstructured":"Hamza T.H.; Chen H.; Hill-Burns E.M.; Rhodes S.L.; Montimurro J.; Kay D.M.; Tenesa A.; Kusel V.I.; Sheehan P.; Eaaswarkhanth M.; Yearout D.; Samii A.; Roberts J.W.; Agarwal P.; Bordelon Y.; Park Y.; Wang L.; Gao J.; Vance J.M.; Kendler K.S.; Bacanu S.A.; Scott W.K.; Ritz B.; Nutt J.; Factor S.A.; Zabetian C.P.; Payami H.; Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson\u2019s disease modifier gene via interaction with coffee. PLoS Genet  2011,7(8),e1002237","journal-title":"PLoS Genet"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1468-1331.2011.03353.x","volume":"18","author":"Popat R.A.","year":"2011","unstructured":"Popat R.A.; Van Den Eeden S.K.; Tanner C.M.; Kamel F.; Umbach D.M.; Marder K.; Mayeux R.; Ritz B.; Ross G.W.; Petrovitch H.; Topol B.; McGuire V.; Costello S.; Manthripragada A.D.; Southwick A.; Myers R.M.; Nelson L.M.; Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson\u2019s disease. Eur J Neurol  2011,18(5),756-765","journal-title":"Eur J Neurol"},{"key":"ref=253","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00213-010-1900-1","volume":"211","author":"Yang A.","year":"2010","unstructured":"Yang A.; Palmer A.A.; de Wit H.; Genetics of caffeine consumption and responses to caffeine. Psychopharmacology (Berl)  2010,211(3),245-257","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s007020050067","volume":"105","author":"Hoyer S.","year":"1998","unstructured":"Hoyer S.; Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm (Vienna)  1998,105(4),415-422","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"Baggio L.L.","year":"2007","unstructured":"Baggio L.L.; Drucker D.J.; Biology of Incretins: GLP-1 and GIP. Gastroenterology  2007,132(6),2131-2157","journal-title":"Gastroenterology"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nrendo.2009.48","volume":"5","author":"Lovshin J.A.","year":"2009","unstructured":"Lovshin J.A.; Drucker D.J.; Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol  2009,5(5),262-269","journal-title":"Nat Rev Endocrinol"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/j.1471-4159.2004.02914.x","volume":"92","author":"Alvarez E.","year":"2005","unstructured":"Alvarez E.; Mart\u00ednez M.D.; Roncero I.; Chowen J.A.; Garc\u00eda-Cuartero B.; Gispert J.D.; Sanz C.; V\u00e1zquez P.; Maldonado A.; De C\u00e1ceres J.; Desco M.; Pozo M.A.; Bl\u00e1zquez E.; The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem  2005,92(4),798-806","journal-title":"J Neurochem"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jnr.21483","volume":"86","author":"Bertilsson G.","year":"2008","unstructured":"Bertilsson G.; Patrone C.; Zachrisson O.; Andersson A.; Dannaeus K.; Heidrich J.; Kortesmaa J.; Mercer A.; Nielsen E.; R\u00f6nnholm H.; Wikstr\u00f6m L.; Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson\u2019s disease. J Neurosci Res  2008,86(2),326-338","journal-title":"J Neurosci Res"},{"key":"ref=259","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1073\/pnas.0806720106","volume":"106","author":"Li Y.","year":"2009","unstructured":"Li Y.; Perry T.; Kindy M.S.; Harvey B.K.; Tweedie D.; Holloway H.W.; Powers K.; Shen H.; Egan J.M.; Sambamurti K.; Brossi A.; Lahiri D.K.; Mattson M.P.; Hoffer B.J.; Wang Y.; Greig N.H.; GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA  2009,106(4),1285-1290","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=260","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/brain\/awx044","volume":"140","author":"Bassil F.","year":"2017","unstructured":"Bassil F.; Canron M.H.; Vital A.; Bezard E.; Li Y.; Greig N.H.; Gulyani S.; Kapogiannis D.; Fernagut P.O.; Meissner W.G.; Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain  2017,140(5),1420-1436","journal-title":"Brain"},{"key":"ref=261","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1677\/JOE-09-0132","volume":"202","author":"Kim S.","year":"2009","unstructured":"Kim S.; Moon M.; Park S.; Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson\u2019s disease. J Endocrinol  2009,202(3),431-439","journal-title":"J Endocrinol"},{"key":"ref=262","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"Athauda D.","year":"2017","unstructured":"Athauda D.; Maclagan K.; Skene S.S.; Bajwa-Joseph M.; Letchford D.; Chowdhury K.; Hibbert S.; Budnik N.; Zampedri L.; Dickson J.; Li Y.; Aviles-Olmos I.; Warner T.T.; Limousin P.; Lees A.J.; Greig N.H.; Tebbs S.; Foltynie T.; Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet  2017,390(10103),1664-1675","journal-title":"Lancet"},{"key":"ref=263","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/bs.irn.2020.02.007","volume":"155","author":"Markaki I.","year":"2020","unstructured":"Markaki I.; Winther K.; Catrina S.B.; Svenningsson P.; Repurposing GLP1 agonists for neurodegenerative diseases. Int Rev Neurobiol  2020,155,91-112","journal-title":"Int Rev Neurobiol"},{"key":"ref=264","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.cmet.2011.09.010","volume":"14","author":"De Silva A.","year":"2011","unstructured":"De Silva A.; Salem V.; Long C.J.; Makwana A.; Newbould R.D.; Rabiner E.A.; Ghatei M.A.; Bloom S.R.; Matthews P.M.; Beaver J.D.; Dhillo W.S.; The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab  2011,14(5),700-706","journal-title":"Cell Metab"},{"key":"ref=265","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.2337\/dc12-1925","volume":"36","author":"Schl\u00f6gl H.","year":"2013","unstructured":"Schl\u00f6gl H.; Kabisch S.; Horstmann A.; Lohmann G.; M\u00fcller K.; Lepsien J.; Busse-Voigt F.; Kratzsch J.; Pleger B.; Villringer A.; Stumvoll M.; Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diabetes Care  2013,36(7),1933-1940","journal-title":"Diabetes Care"},{"key":"ref=266","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","volume":"76","author":"Athauda D.","year":"2019","unstructured":"Athauda D.; Gulyani S.; Karnati H.; Li Y.; Tweedie D.; Mustapic M.; Chawla S.; Chowdhury K.; Skene S.S.; Greig N.H.; Kapogiannis D.; Foltynie T.; Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial. JAMA Neurol  2019,76(4),420-429","journal-title":"JAMA Neurol"},{"key":"ref=267","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1212\/01.wnl.0000262033.01945.9a","volume":"68","author":"Oakley A.E.","year":"2007","unstructured":"Oakley A.E.; Collingwood J.F.; Dobson J.; Love G.; Perrott H.R.; Edwardson J.A.; Elstner M.; Morris C.M.; Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology  2007,68(21),1820-1825","journal-title":"Neurology"},{"key":"ref=268","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(14)70117-6","volume":"13","author":"Ward R.J.","year":"2014","unstructured":"Ward R.J.; Zucca F.A.; Duyn J.H.; Crichton R.R.; Zecca L.; The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol  2014,13(10),1045-1060","journal-title":"Lancet Neurol"},{"key":"ref=269","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00702-010-0531-3","volume":"118","author":"Dexter D.T.","year":"2011","unstructured":"Dexter D.T.; Statton S.A.; Whitmore C.; Freinbichler W.; Weinberger P.; Tipton K.F.; Della Corte L.; Ward R.J.; Crichton R.R.; Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson\u2019s disease after peripheral administration. J Neural Transm (Vienna)  2011,118(2),223-231","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=270","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/ars.2013.5593","volume":"21","author":"Devos D.","year":"2014","unstructured":"Devos D.; Moreau C.; Devedjian J.C.; Kluza J.; Petrault M.; Laloux C.; Jonneaux A.; Ryckewaert G.; Gar\u00e7on G.; Rouaix N.; Duhamel A.; Jissendi P.; Dujardin K.; Auger F.; Ravasi L.; Hopes L.; Grolez G.; Firdaus W.; Sablonni\u00e8re B.; Strubi-Vuillaume I.; Zahr N.; Dest\u00e9e A.; Corvol J.C.; P\u00f6ltl D.; Leist M.; Rose C.; Defebvre L.; Marchetti P.; Cabantchik Z.I.; Bordet R.; Targeting chelatable iron as a therapeutic modality in Parkinson\u2019s disease. Antioxid Redox Signal  2014,21(2),195-210","journal-title":"Antioxid Redox Signal"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501312703240826070530","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/233947\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501312703240826070530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T01:23:37Z","timestamp":1731029017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/233947\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":270,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501312703240826070530","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}